@NP	New serum-derived albumin scaffold	1
@NP	adipose-derived stem cells and olfactory ensheathing cells	48
@NP	adipose-derived stem cells	48
@NP	olfactory ensheathing cells	79
@NP	spinal cord	121
@NP	rats Amaia Ferrero-Gutierrez1 * , Yolanda Menendez-Menendez1 *	141
@NP	rats Amaia Ferrero-Gutierrez1 * , Yolanda Menendez-Menendez1	141
@NP	rats	141
@NP	Amaia Ferrero-Gutierrez1 * , Yolanda Menendez-Menendez1	147
@NP	Amaia Ferrero-Gutierrez1 *	147
@NP	Yolanda Menendez-Menendez1	174
@NP	Maria Alvarez-Viejo1 , Alvaro Meana2 and Jesus Otero1 1Transplant	203
@NP	Maria Alvarez-Viejo1	203
@NP	Alvaro Meana2	225
@NP	Jesus Otero1 1Transplant	243
@NP	Cell Therapy Unit	272
@NP	Hospital Universitario Central de Asturias	291
@NP	Oviedo , Spain and 2Tissue Engineering Research Unit	335
@NP	Centro Comunitario de Sangre y Tejidos de Asturias	388
@NP	Centro Comunitario de Sangre	388
@NP	y Tejidos de Asturias	417
@NP	Oviedo	440
@NP	Spain	448
@NP	U714 Ciber Enfermedades Raras -LRB- CIBERER -RRB- .	455
@NP	U714 Ciber Enfermedades Raras	455
@NP	CIBERER	486
@NP	These authors	497
@NP	this work	539
@NP	Summary .	552
@NP	Recent advances	561
@NP	spinal cord injury	580
@NP	SCI	600
@NP	research and cell culture techniques and biomaterials	605
@NP	promising new treatments for patients with SCI or other nerve injuries	667
@NP	promising new treatments	667
@NP	patients with SCI or other nerve injuries	696
@NP	patients	696
@NP	SCI or other nerve injuries	710
@NP	SCI	710
@NP	other nerve injuries	717
@NP	Biomaterial scaffolds	739
@NP	a substrate	766
@NP	cells	791
@NP	a tissue in a controlled manner	820
@NP	a tissue	820
@NP	a controlled manner	832
@NP	This study	853
@NP	axon regeneration and locomotor recovery in rats	887
@NP	axon regeneration and locomotor recovery	887
@NP	rats	931
@NP	spinal cord injury	941
@NP	a novel serumderived albumin scaffold	973
@NP	adipose	1023
@NP	stem cells -LRB- ADSCs -RRB- and olfactory ensheathing cells -LRB- OECs -RRB-	1039
@NP	stem cells -LRB- ADSCs -RRB-	1039
@NP	stem cells	1039
@NP	ADSCs	1051
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	1062
@NP	olfactory ensheathing cells	1062
@NP	OECs	1091
@NP	OECs	1098
@NP	promising candidates	1118
@NP	the treatment of SCI	1143
@NP	the treatment	1143
@NP	SCI	1160
@NP	ADSCs	1169
@NP	the ability to differentiate into neural lineages	1180
@NP	neural lineages	1214
@NP	In vitro experiments	1231
@NP	ADSCs and OECs	1266
@NP	the scaffold	1292
@NP	specific markers of their cell types	1336
@NP	specific markers	1336
@NP	their cell types	1356
@NP	the scaffold	1390
@NP	Rats treated with scaffold plus cells	1404
@NP	Rats	1404
@NP	scaffold plus cells	1422
@NP	scaffold	1422
@NP	cells	1436
@NP	locomotor skills	1449
@NP	several time points	1469
@NP	45 days	1494
@NP	that	1514
@NP	those recorded in control injured	1538
@NP	those	1538
@NP	control injured	1556
@NP	control	1556
@NP	Astrocytic scars and tissue regeneration	1592
@NP	histological and immunohistochemical techniques	1651
@NP	the scaffold	1723
@NP	a significant role	1760
@NP	glial scar formation and filling of the lesion cavity	1791
@NP	glial scar formation and filling	1791
@NP	the lesion cavity	1827
@NP	cells	1850
@NP	the presence of ADSCs and OECs in the scaffold	1857
@NP	the presence	1857
@NP	ADSCs and OECs in the scaffold	1873
@NP	ADSCs and OECs	1873
@NP	the scaffold	1891
@NP	the appearance of cells	1911
@NP	the appearance	1911
@NP	cells	1929
@NP	markers of neurons and axons	1946
@NP	markers	1946
@NP	neurons and axons	1957
@NP	the injury site	1978
@NP	Our findings	1995
@NP	the clinical feasibility	2017
@NP	an albumin scaffold	2045
@NP	ADSCs and OECs	2077
@NP	a treatment candidate for use in spinal cord injury repair studies	2095
@NP	a treatment candidate	2095
@NP	use in spinal cord injury repair studies	2121
@NP	use	2121
@NP	spinal cord injury repair studies	2128
@NP	Introduction Spinal cord injury -LRB- SCI -RRB-	2164
@NP	Introduction Spinal cord injury	2164
@NP	Introduction	2164
@NP	Spinal cord injury	2177
@NP	SCI	2197
@NP	a devastating condition	2205
@NP	partial or complete sensory and motor loss	2253
@NP	partial or complete sensory	2253
@NP	motor loss	2285
@NP	the level of injury	2302
@NP	the level	2302
@NP	injury	2315
@NP	SCI	2341
@NP	axonal structural and electrophysiological abnormalities	2346
@NP	both gray and white matter -LRB- Balentine , 1978 -RRB-	2418
@NP	both gray and white matter	2418
@NP	Balentine , 1978	2446
@NP	Balentine	2446
@NP	1978	2457
@NP	Trauma	2464
@NP	the death of neurons and glial cells as well as axon tract injury	2478
@NP	the death of neurons and glial cells	2478
@NP	the death	2478
@NP	neurons and glial cells	2491
@NP	neurons	2491
@NP	glial cells	2503
@NP	axon tract injury	2526
@NP	dead neurons	2551
@NP	axons are not spontaneously regenerated	2593
@NP	axons	2593
@NP	functional disorders	2634
@NP	Cadelli et al. , 1992 ; Schwab and Caroni , 2008	2670
@NP	Cadelli	2670
@NP	et al. , 1992 ; Schwab and Caroni , 2008	2678
@NP	et al. , 1992	2678
@NP	et al.	2678
@NP	1992	2686
@NP	Schwab and Caroni , 2008	2692
@NP	Schwab and Caroni	2692
@NP	2008	2711
@NP	The lesion site produced by SCI	2718
@NP	The lesion site	2718
@NP	SCI	2746
@NP	many obstacles	2756
@NP	tissue and cell regeneration	2785
@NP	Events subsequent to SCI	2815
@NP	Events	2815
@NP	SCI	2836
@NP	the formation of a cystic cavity	2848
@NP	the formation	2848
@NP	a cystic cavity	2865
@NP	the injury site	2884
@NP	a glial and fibrous scar , composed of mainly reactive astrocytes	2929
@NP	a glial and fibrous scar	2929
@NP	mainly reactive astrocytes	2967
@NP	a physical barrier	3011
@NP	spontaneous regeneration	3033
@NP	Fawcett and Asher , 1999 ; Brazda and Müller , 2009	3059
@NP	Fawcett and Asher	3059
@NP	1999 ; Brazda and Müller	3078
@NP	1999	3078
@NP	Brazda and Müller	3084
@NP	2009	3104
@NP	addition	3114
@NP	the demyelination that occurs after SCI	3124
@NP	the demyelination	3124
@NP	SCI	3160
@NP	several inhibitory molecules and signals	3173
@NP	this lack	3233
@NP	regeneration -LRB- McGee and Strittmatter , 2003 ; Busch and Silver , 2007 -RRB-	3246
@NP	regeneration	3246
@NP	McGee and Strittmatter , 2003 ; Busch and Silver , 2007	3260
@NP	McGee and Strittmatter	3260
@NP	2003 ; Busch and Silver	3284
@NP	2003	3284
@NP	Busch and Silver	3290
@NP	2007	3308
@NP	Preliminary empirical experiments	3315
@NP	neuronal functions	3388
@NP	injured axons	3436
@NP	lost neurons	3464
@NP	cell transplantation -LRB- Li et al. , 2004 ; Wang et al. , 2006 -RRB-	3480
@NP	cell transplantation	3480
@NP	Li	3502
@NP	et al. , 2004 ; Wang et al. , 2006	3505
@NP	et al.	3505
@NP	2004 ; Wang et al.	3513
@NP	2004	3513
@NP	Wang et al.	3519
@NP	Wang	3519
@NP	et al.	3524
@NP	2006	3532
@NP	central nervous system lesions	3539
@NP	glial cells	3574
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	3595
@NP	olfactory ensheathing cells	3595
@NP	OECs	3624
@NP	Raisman , 2001 ; Barnett and Riddell , 2004	3631
@NP	Raisman	3631
@NP	2001 ; Barnett and Riddell	3640
@NP	2001	3640
@NP	Barnett and Riddell	3646
@NP	2004	3667
@NP	OECs	3674
@NP	astrocytic scars	3721
@NP	axonal regrowth	3761
@NP	neural regeneration and functional reconstruction -LRB- Raisman , 1985 -RRB-	3788
@NP	neural regeneration and functional reconstruction	3788
@NP	regeneration	3795
@NP	Raisman , 1985	3839
@NP	Raisman	3839
@NP	1985	3848
@NP	In vitro and in vivo studies	3855
@NP	vivo	3871
@NP	the injection of OECs at the injury site	3900
@NP	the injection	3900
@NP	OECs at the injury site	3917
@NP	OECs	3917
@NP	the injury site	3925
@NP	a favorable environment	3949
@NP	the regeneration and remyelination of central cord axons	3977
@NP	the regeneration and remyelination	3977
@NP	central cord axons	4015
@NP	functional recovery	4056
@NP	animal models	4079
@NP	SCI	4096
@NP	Groves et al. , 1993 ; Ramon-Cueto et al. , 1998 ; Radtke et al. , 2009	4101
@NP	Groves	4101
@NP	et al. , 1993 ; Ramon-Cueto et al. , 1998 ; Radtke et al. , 2009	4108
@NP	et al. , 1993	4108
@NP	et al.	4108
@NP	1993	4116
@NP	Ramon-Cueto et al. , 1998	4122
@NP	Ramon-Cueto	4122
@NP	et al. , 1998	4134
@NP	et al.	4134
@NP	1998	4142
@NP	Radtke et al. , 2009	4148
@NP	Radtke	4148
@NP	et al. , 2009	4155
@NP	et al.	4155
@NP	2009	4163
@NP	OEC transplantation	4170
@NP	the availability of functional cells	4212
@NP	the availability	4212
@NP	functional cells	4232
@NP	A promising new cell strategy	4250
@NP	the use of adult mesenchymal stem cells -LRB- MSC -RRB-	4292
@NP	the use	4292
@NP	adult mesenchymal stem cells -LRB- MSC -RRB-	4303
@NP	adult mesenchymal stem cells	4303
@NP	MSC	4333
@NP	Adipose-derived stem cells -LRB- ADSCs -RRB-	4339
@NP	Adipose-derived stem cells	4339
@NP	ADSCs	4367
@NP	a neuronal phenotype	4408
@NP	the possible use of these cells to treat neurological disorders	4462
@NP	the possible use	4462
@NP	these cells	4482
@NP	neurological disorders	4503
@NP	the attention of researchers -LRB- Kang et al. , 2003 -RRB-	4540
@NP	the attention	4540
@NP	researchers -LRB- Kang et al. , 2003 -RRB-	4557
@NP	researchers	4557
@NP	Kang	4570
@NP	et al. , 2003	4575
@NP	et al.	4575
@NP	2003	4583
@NP	the injection of OECs directly into the site of SCI	4599
@NP	the injection	4599
@NP	OECs directly into the site of SCI	4616
@NP	OECs	4616
@NP	the site of SCI	4635
@NP	the site	4635
@NP	SCI	4647
@NP	limited use -LRB- Resnick et al. , 2003 ; Collazos-Castro et al. , 2005 -RRB-	4666
@NP	limited use	4666
@NP	Resnick	4679
@NP	et al. , 2003 ; Collazos-Castro et al. , 2005	4687
@NP	et al.	4687
@NP	2003 ; Collazos-Castro et al.	4695
@NP	2003	4695
@NP	Collazos-Castro et al.	4701
@NP	Collazos-Castro	4701
@NP	et al.	4717
@NP	2005	4725
@NP	some of the neurotrophic factors	4732
@NP	some	4732
@NP	the neurotrophic factors	4740
@NP	OECs	4777
@NP	MSC differentiation	4820
@NP	neurons and glial cells	4845
@NP	neurons	4845
@NP	glial cells	4857
@NP	Jin	4879
@NP	et al. , 2003 ; Tatard et al. , 2007	4883
@NP	et al.	4883
@NP	2003 ; Tatard et al.	4891
@NP	2003	4891
@NP	Tatard et al.	4897
@NP	Tatard	4897
@NP	et al.	4904
@NP	2007	4912
@NP	other authors -LRB- Zhang et al. , 2009 ; Arboleda et al. , 2011 -RRB-	4928
@NP	other authors	4928
@NP	Zhang	4943
@NP	et al. , 2009 ; Arboleda et al. , 2011	4949
@NP	et al.	4949
@NP	2009 ; Arboleda et al.	4957
@NP	2009	4957
@NP	Arboleda et al.	4963
@NP	Arboleda	4963
@NP	et al.	4972
@NP	2011	4980
@NP	the functional improvement in animals with SCI transplanted with MSCs	4996
@NP	the functional improvement	4996
@NP	animals with SCI transplanted with MSCs	5026
@NP	animals	5026
@NP	SCI transplanted with MSCs	5039
@NP	SCI	5039
@NP	MSCs	5061
@NP	the release of trophic factors via a paracrine effect	5083
@NP	the release	5083
@NP	trophic factors via a paracrine effect	5098
@NP	trophic factors	5098
@NP	a paracrine effect	5118
@NP	Biodegradable polymer scaffolds	5138
@NP	a structural support	5184
@NP	the injury site and guide axon regeneration	5215
@NP	Olson	5260
@NP	et al. , 2009 ; Straley et al. , 2010	5266
@NP	et al.	5266
@NP	2009 ; Straley et al.	5274
@NP	2009	5274
@NP	Straley et al.	5280
@NP	Straley	5280
@NP	et al.	5288
@NP	2010	5296
@NP	The scaffold used in the present study	5303
@NP	The scaffold	5303
@NP	the present study	5324
@NP	a biodegradable cross-linked plasma-based matrix	5346
@NP	a three-dimensional substrate	5410
@NP	An essential benefit of this new scaffold	5441
@NP	An essential benefit	5441
@NP	this new scaffold	5465
@NP	it	5491
@NP	the patient 's own blood	5511
@NP	the patient 's	5511
@NP	an autologous scaffold	5554
@NP	the risks	5587
@NP	foreign body reaction or infection -LRB- Gallego et al. , 2010 -RRB-	5600
@NP	foreign body reaction or infection	5600
@NP	Gallego	5636
@NP	et al. , 2010	5644
@NP	et al.	5644
@NP	2010	5652
@NP	effect	5662
@NP	this new scaffold	5670
@NP	many tissue-engineering applications	5699
@NP	previous experimental studies	5744
@NP	we	5774
@NP	its successful use	5787
@NP	bone defects -LRB- Gallego et al. , 2009 , 2010 -RRB-	5816
@NP	bone defects	5816
@NP	Gallego	5830
@NP	et al. , 2009 , 2010	5838
@NP	et al.	5838
@NP	2009	5846
@NP	2010	5852
@NP	The present study	5859
@NP	the effect	5900
@NP	a combination	5914
@NP	adipose	5931
@NP	stem cells -LRB- ADSCs -RRB-	5947
@NP	stem cells	5947
@NP	ADSCs	5959
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	5970
@NP	olfactory ensheathing cells	5970
@NP	OECs	5999
@NP	a novel serum-derived albumin scaffold on SCI	6015
@NP	a novel serum-derived albumin scaffold	6015
@NP	SCI	6057
@NP	Materials and methods Scaffold preparation The scaffold	6063
@NP	Materials	6063
@NP	methods Scaffold preparation The scaffold	6077
@NP	methods	6077
@NP	Scaffold preparation	6085
@NP	The scaffold	6106
@NP	as previously described -LRB- Meana et al. , 2008 ; Gallego et al. , 2010 -RRB-	6134
@NP	as previously described	6134
@NP	as previously	6134
@NP	Meana	6159
@NP	et al. , 2008 ; Gallego et al. , 2010	6165
@NP	et al.	6165
@NP	2008 ; Gallego et al.	6173
@NP	2008	6173
@NP	Gallego et al.	6179
@NP	Gallego	6179
@NP	et al.	6187
@NP	2010	6195
@NP	WO2008/119855	6221
@NP	brief	6239
@NP	10 ml of human venous blood	6246
@NP	10 ml	6246
@NP	human venous blood	6255
@NP	a blood bank	6292
@NP	30 min	6318
@NP	37 °C	6328
@NP	the blood	6340
@NP	15 min at 2000 g	6370
@NP	15 min	6370
@NP	2000 g	6380
@NP	the resultant serum -LRB- 5 ml -RRB-	6391
@NP	the resultant serum	6391
@NP	5 ml	6412
@NP	0.5 ml	6439
@NP	25 % glutaraldehyde -LRB- Merck , Darmstadt , Germany -RRB-	6446
@NP	25 % glutaraldehyde	6446
@NP	Merck	6466
@NP	Darmstadt	6473
@NP	Germany	6484
@NP	a 5 ml disposable syringe	6512
@NP	5 ml	6514
@NP	the serum / glutaraldehyde solution at room temperature for 30 min	6553
@NP	the serum / glutaraldehyde solution at room temperature	6553
@NP	the serum	6553
@NP	glutaraldehyde solution at room temperature	6564
@NP	glutaraldehyde solution	6564
@NP	room temperature	6591
@NP	30 min	6612
@NP	solidification	6625
@NP	it	6641
@NP	-70 °C overnight	6667
@NP	-70 °C	6667
@NP	the syringe	6689
@NP	the frozen solution	6718
@NP	48 h	6758
@NP	a	6781
@NP	ethanol series -LRB- 100-90-80 % -RRB-	6790
@NP	ethanol series	6790
@NP	100-90-80 %	6806
@NP	1 h in each dilution	6835
@NP	1 h	6835
@NP	each dilution	6842
@NP	The tube-shaped scaffold obtained	6857
@NP	The tube-shaped scaffold	6857
@NP	3 mm-diameter , 1-2 mm-thick sections and sterilized in 70 % ethanol for 8 h.	6909
@NP	3 mm-diameter	6909
@NP	1-2 mm-thick sections	6924
@NP	sterilized in 70 % ethanol for 8 h.	6950
@NP	sterilized	6950
@NP	70 % ethanol for 8 h.	6964
@NP	70 % ethanol	6964
@NP	8 h.	6980
@NP	these small tubes of scaffold	6994
@NP	these small tubes	6994
@NP	scaffold	7015
@NP	Dulbecco 's	7044
@NP	Eagle 's medium -LRB- DMEM ; Gibco Invitrogen , Paisley , United Kingdom -RRB-	7064
@NP	Eagle 's medium	7064
@NP	Eagle 's	7064
@NP	DMEM ; Gibco Invitrogen , Paisley , United Kingdom	7080
@NP	DMEM	7080
@NP	Gibco Invitrogen , Paisley , United Kingdom	7086
@NP	cell seeding	7137
@NP	excess fluid	7151
@NP	the scaffolds	7180
@NP	a 24	7209
@NP	culture plate -LRB- Nunc , Darmstadt , Germany -RRB-	7220
@NP	culture plate	7220
@NP	Nunc	7235
@NP	Darmstadt	7241
@NP	Germany	7252
@NP	one scaffold per well	7264
@NP	one scaffold	7264
@NP	Adipose-derived stem cell -LRB- ADSCs -RRB- cultures 1-2 g	7287
@NP	Adipose-derived stem cell -LRB- ADSCs -RRB- cultures	7287
@NP	ADSCs	7314
@NP	1-2 g	7330
@NP	abdominal mesenteric adipose tissue	7339
@NP	Wistar rats	7393
@NP	anesthesia	7411
@NP	isoflurane inhalation -LRB- Esteve laboratories , Milan , Italy -RRB-	7433
@NP	isoflurane inhalation	7433
@NP	Esteve laboratories	7456
@NP	Milan	7477
@NP	Italy	7484
@NP	three times	7499
@NP	phosphate-buffered saline	7514
@NP	PBS	7541
@NP	PAA Laboratories GmbH , Cölbe , Germany	7546
@NP	PAA Laboratories GmbH	7546
@NP	Cölbe	7569
@NP	Germany	7576
@NP	a test tube	7608
@NP	0.1 % collagenase I -LRB- Sigma-Aldrich , Madrid , Spain -RRB-	7634
@NP	0.1 % collagenase I	7634
@NP	Sigma-Aldrich	7654
@NP	Madrid	7669
@NP	Spain	7677
@NP	DMEM -LRB- Gibco Invitrogen -RRB-	7687
@NP	DMEM	7687
@NP	Gibco Invitrogen	7693
@NP	the suspension	7712
@NP	1 h at 37 °C	7755
@NP	1 h	7755
@NP	37 °C	7762
@NP	Digestion	7768
@NP	fetal bovine serum -LRB- FBS ; Gibco Invitrogen -RRB-	7800
@NP	fetal bovine serum	7800
@NP	FBS ; Gibco Invitrogen	7820
@NP	FBS	7820
@NP	Gibco Invitrogen	7825
@NP	a 0.40 μm cell strainer -LRB- BD Bioscience , Madrid , Spain -RRB-	7868
@NP	a 0.40 μm cell strainer	7868
@NP	BD Bioscience	7893
@NP	Madrid	7908
@NP	Spain	7916
@NP	centrifuging at 500 g for 10 min	7927
@NP	centrifuging	7927
@NP	500 g for 10 min	7943
@NP	500 g	7943
@NP	10 min	7953
@NP	the cells	7961
@NP	25 cm2 polystyrene flasks -LRB- Cultek , Madrid , Spain -RRB-	7986
@NP	25 cm2 polystyrene flasks	7986
@NP	Cultek	8013
@NP	Madrid	8021
@NP	Spain	8029
@NP	an ADSCs culture medium	8039
@NP	low-dose sugar DMEM	8077
@NP	Gibco Invitrogen	8098
@NP	10 % FBS	8134
@NP	100 U/ml penicillin -LRB- Gibco Invitrogen -RRB-	8144
@NP	100 U/ml penicillin	8144
@NP	Gibco Invitrogen	8165
@NP	100 μg/ml streptomycin -LRB- Gibco Invitrogen -RRB-	8188
@NP	100 μg/ml streptomycin	8188
@NP	Gibco Invitrogen	8212
@NP	Cells	8231
@NP	a controlled atmosphere -LRB- 37 °C , 5 % CO2 -RRB-	8254
@NP	a controlled atmosphere	8254
@NP	37 °C , 5 % CO2	8279
@NP	37 °C	8279
@NP	5 % CO2	8285
@NP	48 h	8296
@NP	the medium	8302
@NP	unattached cells	8336
@NP	the medium	8374
@NP	every 2-3 days	8401
@NP	the 14th day	8424
@NP	the cells	8454
@NP	trypsin -LRB- 0.25 % w/v ; Gibco Invitrogen -RRB-	8483
@NP	trypsin	8483
@NP	0.25 % w/v ; Gibco Invitrogen	8492
@NP	0.25 % w/v	8492
@NP	Gibco Invitrogen	8504
@NP	four times	8535
@NP	their use	8553
@NP	Olfactory ensheathing cells -LRB- OECs -RRB- cultures	8564
@NP	Olfactory ensheathing cells	8564
@NP	OECs	8593
@NP	cultures	8599
@NP	purification	8612
@NP	Primary olfactory bulb -LRB- OB -RRB- cells	8625
@NP	OB	8649
@NP	adult female Wistar rats	8664
@NP	three months old ; Harlan Laboratories , Germany	8690
@NP	three months old	8690
@NP	Harlan Laboratories , Germany	8708
@NP	Harlan Laboratories	8708
@NP	Germany	8729
@NP	detail -LRB- Gudiño-Cabrera and Nieto-Sampedro , 1996 -RRB-	8778
@NP	detail	8778
@NP	Gudiño-Cabrera and Nieto-Sampedro , 1996	8786
@NP	Gudiño-Cabrera and Nieto-Sampedro	8786
@NP	1996	8821
@NP	The method used to purify OECs from these primary OB cultures	8828
@NP	The method	8828
@NP	OECs	8854
@NP	these primary OB cultures	8864
@NP	the original protocol -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 -RRB-	8908
@NP	the original protocol	8908
@NP	Ramon-Cueto and Nieto-Sampedro , 1994	8931
@NP	Ramon-Cueto and Nieto-Sampedro	8931
@NP	1994	8963
@NP	14 days	8976
@NP	OECs	8999
@NP	other cell types in primary cultures	9024
@NP	other cell types	9024
@NP	primary cultures	9044
@NP	immunoaffinity	9064
@NP	an antibody	9085
@NP	the p-75 nerve growth factor receptor	9105
@NP	p-75 NGFR ; Chemicon , Millipore , Madrid , Spain	9144
@NP	p-75 NGFR	9144
@NP	Chemicon , Millipore , Madrid , Spain	9155
@NP	1:1000	9192
@NP	Cells from primary cultures	9201
@NP	Cells	9201
@NP	primary cultures	9212
@NP	0.25 % trypsin	9248
@NP	200 g ; 10 min	9276
@NP	200 g	9276
@NP	10 min	9283
@NP	the p-75 NGFR antibody for 45 min	9311
@NP	the p-75 NGFR antibody	9311
@NP	45 min	9338
@NP	room temperature	9348
@NP	the cells	9372
@NP	PBS/BSA/EDTA	9403
@NP	monoclonal IgG	9435
@NP	Dynabeads	9462
@NP	M-450	9472
@NP	DBM-450	9479
@NP	magnetic beads , coated with goat anti-mouse IgG	9488
@NP	magnetic beads	9488
@NP	goat anti-mouse IgG	9516
@NP	Miltenyi Biotec , Madrid , Spain	9537
@NP	Miltenyi Biotec	9537
@NP	Madrid , Spain	9554
@NP	30 min at 4 °C	9573
@NP	30 min	9573
@NP	4 °C	9583
@NP	The cells	9588
@NP	the magnetic beads	9627
@NP	the cells	9665
@NP	p75-NGFR	9696
@NP	the help of a potent permanent magnet -LRB- 69 -RRB-	9710
@NP	the help	9710
@NP	a potent permanent magnet -LRB- 69 -RRB-	9722
@NP	a potent permanent magnet	9722
@NP	69	9749
@NP	the magnetic bead-OEC complexes	9763
@NP	These complexes	9796
@NP	three times	9824
@NP	PBS/BSA/EDTA	9839
@NP	the OECs	9856
@NP	a poly-L-lysine-treated	9877
@NP	Sigma-Aldrich ; average molecular weight	9902
@NP	Sigma-Aldrich	9902
@NP	average molecular weight	9917
@NP	30,000 ; 50 mg/ml	9943
@NP	30,000	9943
@NP	50 mg/ml	9951
@NP	25 cm2 flask followed by incubation for 48 h in an OEC culture medium	9961
@NP	25 cm2 flask	9961
@NP	incubation for 48 h in an OEC culture medium	9986
@NP	incubation	9986
@NP	48 h in an OEC culture medium	10001
@NP	48 h	10001
@NP	an OEC culture medium	10009
@NP	1:1 mixture	10032
@NP	DMEM and Ham 's F-12 medium -LRB- Lonza , Barcelona , Spain -RRB-	10047
@NP	DMEM	10047
@NP	Ham 's F-12 medium -LRB- Lonza , Barcelona , Spain -RRB-	10056
@NP	Ham 's F-12 medium	10056
@NP	Ham 's	10056
@NP	Lonza	10075
@NP	Barcelona	10082
@NP	Spain	10093
@NP	10 % FBS , 100 U/ml penicillin , and 100 μg/ml streptomycin	10118
@NP	10 % FBS	10118
@NP	100 U/ml penicillin	10127
@NP	100 μg/ml streptomycin	10152
@NP	37 °C in a 5 % CO2 atmosphere	10179
@NP	37 °C	10179
@NP	a 5 % CO2 atmosphere	10187
@NP	Cell seeding Confluent cultures of ADSCs -LRB- fourth passage -RRB- and OECs	10208
@NP	Cell seeding Confluent cultures	10208
@NP	ADSCs -LRB- fourth passage -RRB- and OECs	10243
@NP	ADSCs -LRB- fourth passage -RRB-	10243
@NP	ADSCs	10243
@NP	fourth passage	10250
@NP	OECs	10270
@NP	a Neubauer hemocytometer	10307
@NP	The cells released	10333
@NP	The cells	10333
@NP	DMEM	10370
@NP	10 % FBS	10386
@NP	the DMEM	10400
@NP	the ADSCs and OECs	10427
@NP	scaffold culture medium	10461
@NP	DMEM containing 10 % FBS , 100 U/ml penicillin	10486
@NP	DMEM	10486
@NP	10 % FBS , 100 U/ml penicillin	10502
@NP	10 % FBS	10502
@NP	100 U/ml penicillin	10511
@NP	100 μg/ml streptomycin	10535
@NP	25 ng/ml NT-3 -LRB- Sigma -RRB- and 100 ng/ml NGF -LRB- Sigma - Aldrich -RRB-	10563
@NP	25 ng/ml NT-3	10563
@NP	Sigma	10578
@NP	100 ng/ml NGF	10589
@NP	Sigma - Aldrich	10604
@NP	Sigma	10604
@NP	Aldrich	10611
@NP	ADSCs -LRB- 0.5 ml -RRB- and 5x105 OECs -LRB- 0.5 ml -RRB-	10634
@NP	ADSCs -LRB- 0.5 ml -RRB-	10634
@NP	ADSCs	10634
@NP	0.5 ml	10641
@NP	5x105 OECs -LRB- 0.5 ml -RRB-	10653
@NP	5x105 OECs	10653
@NP	0.5 ml	10665
@NP	the scaffolds in the wells	10690
@NP	the scaffolds	10690
@NP	the wells	10707
@NP	The scaffolds	10718
@NP	48 h	10760
@NP	the cells	10774
@NP	The culture medium	10795
@NP	week	10840
@NP	The cells	10846
@NP	7 days at 37 °C in a humidified atmosphere of 5 % CO2	10876
@NP	7 days	10876
@NP	37 °C in a humidified atmosphere of 5 % CO2	10886
@NP	37 °C	10886
@NP	a humidified atmosphere of 5 % CO2	10894
@NP	a humidified atmosphere	10894
@NP	5 % CO2	10921
@NP	In vitro experiments The following in vitro study groups	10929
@NP	In vitro experiments	10929
@NP	The following	10950
@NP	study groups	10973
@NP	Scaffold control -LRB- n = 5 -RRB- : Scaffold alone	11004
@NP	Scaffold control	11004
@NP	n	11022
@NP	5	11026
@NP	Scaffold alone	11030
@NP	Scaffold + ADSCs + OECs -LRB- n = 5 -RRB-	11046
@NP	Scaffold + ADSCs + OECs	11046
@NP	Scaffold + ADSCs	11046
@NP	OECs	11065
@NP	n	11071
@NP	5	11075
@NP	ADSCs and OECs co-cultured in the scaffold	11079
@NP	ADSCs and OECs	11079
@NP	the scaffold	11109
@NP	electron microscopy -LRB- SEM -RRB-	11132
@NP	electron microscopy	11132
@NP	SEM	11153
@NP	The structural features of the scaffold and cells in the scaffold	11158
@NP	The structural features	11158
@NP	the scaffold and cells in the scaffold	11185
@NP	the scaffold and cells	11185
@NP	the scaffold	11211
@NP	ADSCs and OECs	11225
@NP	ADSCs	11225
@NP	OECs	11235
@NP	scanning electron microscopy	11258
@NP	The scaffolds	11288
@NP	2 % phosphate-buffered glutaraldehyde 0.1 M	11316
@NP	2 % phosphate-buffered glutaraldehyde	11316
@NP	Panreac	11360
@NP	Barcelona	11369
@NP	Spain	11380
@NP	12 h.	11391
@NP	The fixed samples	11397
@NP	a	11434
@NP	series of acetone -LRB- 30-50-70 - 90-100 % ; Merck , Darmstadt , Germany -RRB-	11443
@NP	series	11443
@NP	acetone -LRB- 30-50-70 - 90-100 % ; Merck , Darmstadt , Germany -RRB-	11453
@NP	acetone	11453
@NP	30-50-70	11462
@NP	90-100 % ; Merck , Darmstadt , Germany	11472
@NP	90-100 %	11472
@NP	Merck , Darmstadt , Germany	11481
@NP	critical point	11534
@NP	CO2 -LRB- Baltec CDP 030 critical point dryer -RRB-	11555
@NP	CO2	11555
@NP	Baltec CDP 030 critical point dryer	11560
@NP	Baltec CDP	11560
@NP	030 critical point dryer	11571
@NP	These samples	11598
@NP	gold	11637
@NP	SEM -LRB- JEOL JSM 6100 , Tokyo , Japan -RRB-	11661
@NP	SEM	11661
@NP	JEOL JSM 6100 , Tokyo , Japan	11666
@NP	JEOL JSM 6100	11666
@NP	Tokyo , Japan	11681
@NP	Assessment of nuclear morphology The scaffolds	11696
@NP	Assessment	11696
@NP	nuclear morphology The scaffolds	11710
@NP	nuclear morphology	11710
@NP	The scaffolds	11729
@NP	4 % paraformaldehyde -LRB- Panreac -RRB-	11767
@NP	4 % paraformaldehyde	11767
@NP	Panreac	11788
@NP	0.1 M PBS at 4 °C	11800
@NP	0.1 M PBS	11800
@NP	4 °C	11813
@NP	PBS	11841
@NP	the scaffolds	11846
@NP	isopentane -LRB- Merck -RRB-	11875
@NP	isopentane	11875
@NP	Merck	11887
@NP	embedded in OCT medium -LRB- Tissue-Tek , Zoeterwoude , Netherlands -RRB-	11898
@NP	embedded in OCT medium	11898
@NP	OCT	11910
@NP	Tissue-Tek	11922
@NP	Zoeterwoude	11934
@NP	Netherlands	11947
@NP	sections	11964
@NP	10 μm-thick cut on a cryostat	11979
@NP	10 μm-thick cut	11979
@NP	a cryostat	11998
@NP	model Jung friocut 2800E , Leica , Heerbrugg , Switzerland	12010
@NP	model Jung friocut 2800E	12010
@NP	Leica	12036
@NP	Heerbrugg	12043
@NP	Switzerland	12054
@NP	The sections	12068
@NP	PBS	12096
@NP	the nuclear fluorescent	12127
@NP	DAPI -LRB- 1.5 μg/ml -RRB-	12155
@NP	DAPI	12155
@NP	1.5 μg/ml	12161
@NP	Vectashield mounting medium	12173
@NP	DAPI ; Vector Laboratories , Peterborough , United Kingdom	12206
@NP	DAPI	12206
@NP	Vector Laboratories , Peterborough , United Kingdom	12212
@NP	Vector Laboratories	12212
@NP	Peterborough , United Kingdom	12233
@NP	coverslips	12280
@NP	Observations and photographs	12292
@NP	an Olympus BX-41 fluorescence microscope	12343
@NP	a digital camera -LRB- model DP71 ; Olympus , Barcelona , Spain -RRB-	12395
@NP	a digital camera	12395
@NP	model DP71 ; Olympus , Barcelona , Spain	12413
@NP	model DP71	12413
@NP	Olympus , Barcelona , Spain	12425
@NP	the results analyzed using the equipment 's image analysis software	12456
@NP	the results	12456
@NP	the equipment 's image analysis software	12483
@NP	the equipment 's	12483
@NP	Immunohistochemical analysis The scaffolds	12524
@NP	Immunohistochemical analysis	12524
@NP	The scaffolds	12553
@NP	4 % paraformaldehyde in 0.1 M PBS at 4 °C	12591
@NP	4 % paraformaldehyde	12591
@NP	0.1 M PBS at 4 °C	12614
@NP	0.1 M PBS	12614
@NP	4 °C	12627
@NP	isopentane	12642
@NP	OCT medium	12669
@NP	sections	12685
@NP	10 μm-thick cut on a cryostat	12700
@NP	10 μm-thick cut	12700
@NP	a cryostat	12719
@NP	immunohistochemistry	12735
@NP	the sections	12757
@NP	glass slides , placed in PBS	12786
@NP	glass slides	12786
@NP	PBS	12810
@NP	endogenous peroxidase	12818
@NP	30 min	12854
@NP	1 % H2O2	12866
@NP	Possible background staining	12875
@NP	sections	12930
@NP	at least 30 min in 5 % BSA -LRB- Merck -RRB-	12943
@NP	at least 30 min	12943
@NP	5 % BSA -LRB- Merck -RRB-	12962
@NP	5 % BSA	12962
@NP	Merck	12970
@NP	PBS	12980
@NP	Sections	12985
@NP	mouse anti-vimentin monoclonal antibody -LRB- Dako , Barcelona , Spain -RRB-	13019
@NP	mouse anti-vimentin monoclonal antibody	13019
@NP	Dako	13060
@NP	Barcelona	13066
@NP	Spain	13077
@NP	1:100	13085
@NP	30 min	13096
@NP	room temperature in a humid chamber	13106
@NP	room temperature	13106
@NP	a humid chamber	13126
@NP	mouse anti-p75 NGFR	13150
@NP	monoclonal antibody -LRB- Millipore -RRB- -LRB- 1:200 -RRB-	13170
@NP	monoclonal antibody -LRB- Millipore -RRB-	13170
@NP	monoclonal antibody	13170
@NP	Millipore	13191
@NP	1:200	13203
@NP	18 h at 4 °C in a humid chamber	13214
@NP	18 h	13214
@NP	4 °C in a humid chamber	13222
@NP	4 °C	13222
@NP	a humid chamber	13229
@NP	further rinsing in PBS	13252
@NP	further rinsing	13252
@NP	PBS	13271
@NP	the sections	13276
@NP	the secondary antibody	13321
@NP	peroxidase -LRB- Dako -RRB- for 30 min	13358
@NP	peroxidase -LRB- Dako -RRB-	13358
@NP	peroxidase	13358
@NP	Dako	13370
@NP	30 min	13380
@NP	room temperature in a humid chamber	13390
@NP	room temperature	13390
@NP	a humid chamber	13410
@NP	The complexes antibody-vimentin and antibody-p-75 NGFR	13427
@NP	The complexes antibody-vimentin	13427
@NP	antibody-p-75 NGFR	13463
@NP	the REAL EnVision Detection system kit -LRB- Dako -RRB-	13512
@NP	the REAL EnVision Detection system kit	13512
@NP	Dako	13552
@NP	This kit	13559
@NP	a 3 ' -3 ' - diaminobenzidine -LRB- DAB -RRB-	13573
@NP	a 3 ' -3	13573
@NP	a 3	13573
@NP	-3	13577
@NP	diaminobenzidine -LRB- DAB -RRB-	13582
@NP	diaminobenzidine	13582
@NP	DAB	13600
@NP	chromogen	13610
@NP	vimentin and p75-NGFR-positive cells brown	13630
@NP	sections	13682
@NP	a hydrophobic medium -LRB- Entellan ; Merck -RRB-	13707
@NP	a hydrophobic medium	13707
@NP	Entellan ; Merck	13729
@NP	Entellan	13729
@NP	Merck	13739
@NP	Other sections	13747
@NP	hematoxylin and eosin -LRB- H&E -RRB- for microscopy examination	13780
@NP	hematoxylin and eosin -LRB- H&E -RRB-	13780
@NP	hematoxylin and eosin	13780
@NP	H&E	13803
@NP	microscopy examination	13812
@NP	Observations and photographs	13836
@NP	an Olympus BX-41 microscope	13887
@NP	a digital camera -LRB- Olympus -RRB-	13926
@NP	a digital camera	13926
@NP	Olympus	13944
@NP	the results analyzed using the equipment 's image analysis software	13957
@NP	the results	13957
@NP	the equipment 's image analysis software	13984
@NP	the equipment 's	13984
@NP	In vivo experiments Spinal cord injury model The SCI model used	14025
@NP	In vivo experiments	14025
@NP	Spinal cord injury model The SCI model	14045
@NP	Spinal cord injury model	14045
@NP	The SCI model	14070
@NP	Demjen	14111
@NP	et al.	14118
@NP	2004	14126
@NP	injury	14141
@NP	the	14172
@NP	a small hinge uncut -LRB- the cord is thus around 80 % transected -RRB-	14184
@NP	a small hinge uncut	14184
@NP	the cord	14205
@NP	80 %	14229
@NP	This	14246
@NP	the formation of a central cavity	14262
@NP	the formation	14262
@NP	a central cavity	14279
@NP	some axons	14305
@NP	Animals injured in this manner	14328
@NP	Animals	14328
@NP	this manner	14347
@NP	symmetrical paraplegia	14364
@NP	hindlimb movement	14408
@NP	surgery	14444
@NP	SCI	14453
@NP	female Wistar rats	14472
@NP	Laboratory Animal Center , University of Oviedo , Oviedo , Spain	14492
@NP	Laboratory Animal Center	14492
@NP	University of Oviedo	14518
@NP	University	14518
@NP	Oviedo	14532
@NP	Oviedo , Spain	14540
@NP	all matched for age -LRB- 12 weeks old -RRB- and weight -LRB- mean 250 g -RRB-	14556
@NP	all	14556
@NP	age -LRB- 12 weeks old -RRB- and weight -LRB- mean 250 g -RRB-	14572
@NP	age	14572
@NP	12 weeks	14577
@NP	weight	14595
@NP	mean 250 g	14603
@NP	mean	14603
@NP	250 g	14608
@NP	The rats	14616
@NP	isoflurane inhalation -LRB- Esteve -RRB-	14646
@NP	isoflurane inhalation	14646
@NP	Esteve	14669
@NP	aseptic conditions	14684
@NP	the spinal cord	14704
@NP	laminectomy	14735
@NP	vertebral level T7	14750
@NP	fine iridectomy scissors -LRB- FST , Heidelberg , Germany -RRB-	14826
@NP	fine iridectomy scissors	14826
@NP	FST	14852
@NP	Heidelberg	14857
@NP	Germany	14869
@NP	SCI	14885
@NP	the rats	14890
@NP	the different treatment groups	14937
@NP	the spinal cord	14974
@NP	the tissue contraction	15002
@NP	enough room for scaffold insertion	15041
@NP	enough room	15041
@NP	scaffold insertion	15057
@NP	The scaffolds	15077
@NP	the site of spinal cord injury 5 min	15109
@NP	the site	15109
@NP	spinal cord injury 5 min	15121
@NP	injury -LRB- n = 8 per group -RRB-	15152
@NP	injury	15152
@NP	n = 8 per group	15160
@NP	n = 8	15160
@NP	n	15160
@NP	8	15162
@NP	group	15168
@NP	1 hour	15185
@NP	the operation	15198
@NP	the rats	15213
@NP	enrofloxacine -LRB- 8.5 mg/kg -RRB-	15240
@NP	enrofloxacine	15240
@NP	8.5 mg/kg	15255
@NP	once a day for 7 days and buprenorphine -LRB- 0.01 mg/kg -RRB- once a day	15266
@NP	a day	15271
@NP	7 days and buprenorphine -LRB- 0.01 mg/kg -RRB-	15281
@NP	7 days and buprenorphine	15281
@NP	7 days	15281
@NP	buprenorphine	15292
@NP	0.01 mg/kg	15307
@NP	3 days	15334
@NP	The bladders of the animals	15342
@NP	The bladders	15342
@NP	the animals	15358
@NP	once a day	15392
@NP	they	15409
@NP	autonomic bladder function	15428
@NP	The rats	15456
@NP	a climate-controlled , pathogen-free animal house	15478
@NP	a12 h light-dark cycle	15544
@NP	Food and water	15568
@NP	Food	15568
@NP	water	15577
@NP	available ad libitum	15588
@NP	Experiments	15610
@NP	accordance	15640
@NP	the guidelines	15656
@NP	the European Union	15674
@NP	86-609-EU	15694
@NP	Spanish regulations	15709
@NP	BOE 67-8509-12	15730
@NP	1988	15746
@NP	Experimental protocols	15753
@NP	the Committee for Animal Care and Handling of the University of Oviedo	15798
@NP	the Committee	15798
@NP	Animal Care and Handling	15816
@NP	the University of Oviedo	15844
@NP	the University	15844
@NP	Oviedo	15862
@NP	Animal treatment groups	15870
@NP	The following	15894
@NP	vivo	15911
@NP	treatment groups	15916
@NP	Group 1 -LRB- G1 -RRB- , SCI-only : rats subjected to SCI	15951
@NP	Group 1 -LRB- G1 -RRB-	15951
@NP	Group 1	15951
@NP	G1	15960
@NP	rats subjected to SCI	15975
@NP	rats	15975
@NP	SCI	15993
@NP	Group 2 -LRB- G2 -RRB- , SCI + scaffold	16013
@NP	Group 2	16013
@NP	G2	16022
@NP	SCI + scaffold	16027
@NP	scaffold	16033
@NP	rats subjected to SCI and then treated with a cell-free scaffold	16043
@NP	rats	16043
@NP	SCI	16061
@NP	a cell-free scaffold	16087
@NP	Group 3 -LRB- G3 -RRB- , SCI with cell	16109
@NP	Group 3 -LRB- G3 -RRB-	16109
@NP	Group 3	16109
@NP	G3	16118
@NP	SCI with cell	16123
@NP	SCI	16123
@NP	cell	16132
@NP	scaffold	16144
@NP	rats	16154
@NP	SCI	16172
@NP	a scaffold seeded with ADSCs and OECs	16198
@NP	a scaffold	16198
@NP	ADSCs and OECs	16221
@NP	BBB	16246
@NP	Overall motor performance of the animals	16255
@NP	Overall motor performance	16255
@NP	the animals	16284
@NP	the BBB locomotor rating scale	16315
@NP	slight modifications -LRB- Basso et al. , 1995 -RRB-	16351
@NP	slight modifications	16351
@NP	Basso	16373
@NP	et al. , 1995	16379
@NP	et al.	16379
@NP	1995	16387
@NP	Rats	16394
@NP	place on a methacrylate walkway 1 m long	16404
@NP	place	16404
@NP	a methacrylate walkway 1 m long	16413
@NP	a methacrylate walkway	16413
@NP	1 m	16436
@NP	6.2 cm	16449
@NP	The runway	16462
@NP	top of an inclined mirror -LRB- 60 ° angle -RRB-	16487
@NP	top	16487
@NP	an inclined mirror -LRB- 60 ° angle -RRB-	16494
@NP	an inclined mirror	16494
@NP	60 ° angle	16514
@NP	60	16514
@NP	° angle	16516
@NP	the observation of hind-limb movements	16535
@NP	the observation	16535
@NP	hind-limb movements	16554
@NP	Each animal	16575
@NP	the runway	16599
@NP	three times	16610
@NP	each testing session	16626
@NP	the animals	16648
@NP	two observers	16689
@NP	the treatment -LRB- the test was performed in a double-blinded manner -RRB-	16712
@NP	the treatment	16712
@NP	the test	16727
@NP	a double-blinded manner	16753
@NP	Hind-limb locomotion	16779
@NP	0 -LRB- no observable hind-limb movement -RRB-	16816
@NP	0	16816
@NP	no observable hind-limb movement	16819
@NP	21 points -LRB- normal movement -RRB-	16856
@NP	21 points	16856
@NP	normal movement	16867
@NP	The scale	16885
@NP	the sequence of recovering motor features	16911
@NP	the sequence	16911
@NP	recovering motor features	16927
@NP	the same	16961
@NP	the original score	16986
@NP	rats	17012
@NP	their tails early	17035
@NP	the recovery process	17056
@NP	an additional 0.5 points	17078
@NP	a raised tail position -LRB- Demjen et al. , 2004 -RRB-	17118
@NP	a raised tail position	17118
@NP	Demjen	17142
@NP	et al. , 2004	17149
@NP	et al.	17149
@NP	2004	17157
@NP	All animals groups	17164
@NP	day 0 after SCI and once per week thereafter	17198
@NP	day 0	17198
@NP	SCI	17210
@NP	week	17227
@NP	13 weeks post injury	17249
@NP	13 weeks	17249
@NP	Rats	17271
@NP	a video camera	17296
@NP	their performance	17335
@NP	digitalized videos played at one-quarter speed	17372
@NP	digitalized videos	17372
@NP	one-quarter speed	17401
@NP	every treated group , n = 8 except in G2 on day 14 post-injury	17423
@NP	every treated group	17423
@NP	n = 8 except in G2 on day 14 post-injury	17444
@NP	n	17444
@NP	= 8 except in G2 on day 14 post-injury	17445
@NP	8	17446
@NP	G2 on day 14	17458
@NP	G2	17458
@NP	day 14	17464
@NP	the n	17484
@NP	audiovisual problems	17503
@NP	Histological and immunohistochemical analysis The animals	17525
@NP	Histological and immunohistochemical analysis	17525
@NP	The animals	17571
@NP	the different treatment groups	17586
@NP	90 days	17633
@NP	surgery	17647
@NP	the animals	17665
@NP	saline solution	17711
@NP	ice-cold 4 % paraformaldehyde	17740
@NP	The entire spinal cords	17770
@NP	an additional 48-72 h in the same fixative	17828
@NP	an additional 48-72 h	17828
@NP	the same fixative	17853
@NP	the spinal cords	17878
@NP	EDTA solution -LRB- 10 % , Panreac -RRB- for 10 days	17912
@NP	EDTA solution -LRB- 10 % , Panreac -RRB-	17912
@NP	EDTA solution	17912
@NP	10 %	17927
@NP	Panreac	17932
@NP	10 days	17945
@NP	the EDTA solution replenished each day	17958
@NP	the EDTA solution	17958
@NP	each day	17988
@NP	The spinal cords	17998
@NP	approximately 2 cm lengths centered at the injury site analyzed	18034
@NP	approximately 2 cm lengths	18034
@NP	the injury site analyzed	18073
@NP	the injury site	18073
@NP	decalcification	18105
@NP	the spinal cords	18122
@NP	a graded series of ethanol dilutions and embedded in paraffin	18158
@NP	series of ethanol dilutions	18167
@NP	series	18167
@NP	ethanol dilutions	18177
@NP	Sections 20 μm thick	18221
@NP	Sections	18221
@NP	20 μm	18230
@NP	a microtome -LRB- model H310 ; Micron , Waldorf , Germany -RRB-	18262
@NP	a microtome	18262
@NP	model H310 ; Micron , Waldorf , Germany	18275
@NP	model H310	18275
@NP	Micron , Waldorf , Germany	18287
@NP	xylene	18332
@NP	an ethanol series	18354
@NP	PBS	18387
@NP	Some of the sections	18392
@NP	Some	18392
@NP	the sections	18400
@NP	glass slides for histological observations	18429
@NP	glass slides	18429
@NP	histological observations	18446
@NP	H&E and Sirius red staining	18478
@NP	H&E	18478
@NP	Sirius red staining	18486
@NP	immunohistochemical studies	18511
@NP	the sections	18540
@NP	1 % H2O2 for 30 min	18569
@NP	1 % H2O2	18569
@NP	30 min	18581
@NP	PBS	18605
@NP	endogenous peroxidase activity	18619
@NP	incubation with primary antibodies	18658
@NP	incubation	18658
@NP	primary antibodies	18674
@NP	possible background staining	18694
@NP	sections	18749
@NP	al	18762
@NP	30 min in 5 % BSA in PBS	18771
@NP	30 min	18771
@NP	5 % BSA in PBS	18781
@NP	5 % BSA	18781
@NP	PBS	18791
@NP	the anti-tyrosine hydroxylase primary antibody	18807
@NP	slides	18855
@NP	citrate buffer -LRB- pH 6 -RRB- in a pressure cooker	18891
@NP	citrate buffer -LRB- pH 6 -RRB-	18891
@NP	citrate buffer	18891
@NP	pH 6	18907
@NP	a pressure cooker	18916
@NP	The sections	19524
@NP	these primary antibodies overnight at 4 °C in a humid chamber	19557
@NP	these primary antibodies overnight	19557
@NP	4 °C in a humid chamber	19595
@NP	4 °C	19595
@NP	a humid chamber	19602
@NP	further rinsing in PBS	19625
@NP	further rinsing	19625
@NP	PBS	19644
@NP	the sections	19649
@NP	the secondary antibody	19694
@NP	peroxidase -LRB- Dako -RRB- for 30 min	19731
@NP	peroxidase -LRB- Dako -RRB-	19731
@NP	peroxidase	19731
@NP	Dako	19743
@NP	30 min	19753
@NP	room temperature in a humid chamber	19763
@NP	room temperature	19763
@NP	a humid chamber	19783
@NP	The antibody complex	19800
@NP	the REAL EnVision Detection system kit -LRB- Dako -RRB-	19851
@NP	the REAL EnVision Detection system kit	19851
@NP	Dako	19891
@NP	This kit	19898
@NP	a DAB-like chromogen	19912
@NP	All sections	19934
@NP	hematoxylin	19972
@NP	sections	19993
@NP	a hydrophobic medium -LRB- Entellan ; Merck -RRB-	20018
@NP	a hydrophobic medium	20018
@NP	Entellan ; Merck	20040
@NP	Entellan	20040
@NP	Merck	20050
@NP	Observations and photographs	20058
@NP	a Olympus BX-41 microscope	20109
@NP	a digital camera -LRB- Olympus -RRB-	20147
@NP	a digital camera	20147
@NP	Olympus	20165
@NP	the results analyzed using the equipment 's image analysis software	20178
@NP	the results	20178
@NP	the equipment 's image analysis software	20205
@NP	the equipment 's	20205
@NP	Statistical analysis	20246
@NP	statistical analysis	20271
@NP	we	20292
@NP	the program Graphpad InStat	20300
@NP	Windows	20332
@NP	Data for the different groups	20341
@NP	Data	20341
@NP	the different groups	20350
@NP	unpaired two-tailed one-way analysis of variance -LRB- ANOVA -RRB-	20388
@NP	unpaired two-tailed one-way analysis	20388
@NP	variance -LRB- ANOVA -RRB-	20428
@NP	variance	20428
@NP	ANOVA	20438
@NP	a Student 's ttest	20454
@NP	a Student 's	20454
@NP	Data	20473
@NP	means	20494
@NP	S.E.M.	20502
@NP	Figures	20509
@NP	significant differences	20531
@NP	the discussion of the data	20567
@NP	the discussion	20567
@NP	the data	20585
@NP	The level of significance	20595
@NP	The level	20595
@NP	significance	20608
@NP	p	20632
@NP	Results Table 1 .	20641
@NP	Results	20641
@NP	Table 1	20649
@NP	Sirius red and immunohistochemical staining	20658
@NP	the three treatment groups	20722
@NP	Fig. 1 .	20751
@NP	Fig.	20751
@NP	1	20756
@NP	Scanning electron microphotographs	20759
@NP	cross sections	20797
@NP	the microstructure	20820
@NP	-LRB- A -RRB- the albumin scaffold , -LRB- B -RRB- adipose-derived stem cells	20843
@NP	-LRB- A -RRB- the albumin scaffold , -LRB- B -RRB-	20843
@NP	-LRB- A -RRB-	20843
@NP	the albumin scaffold	20847
@NP	B	20870
@NP	adipose-derived stem cells	20873
@NP	ADSCs	20901
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	20912
@NP	olfactory ensheathing cells	20912
@NP	OECs	20941
@NP	the scaffold	20958
@NP	Fig. 2 .	20973
@NP	Fig.	20973
@NP	2	20978
@NP	Effect	20981
@NP	the scaffold on the nuclear morphology	20991
@NP	the scaffold	20991
@NP	the nuclear morphology	21007
@NP	adipose-derived stem cells	21033
@NP	ADSCs	21061
@NP	olfactory ensheathing cells	21072
@NP	OECs	21101
@NP	the cells	21125
@NP	the scaffold for 7 days	21138
@NP	the scaffold	21138
@NP	7 days	21155
@NP	cell nuclei	21163
@NP	the DNA-binding fluorescent	21208
@NP	DAPI	21240
@NP	the autofluorescence of the scaffold	21251
@NP	the autofluorescence	21251
@NP	the scaffold	21275
@NP	A	21292
@NP	A.	21296
@NP	Control -LRB- scaffold alone -RRB- .	21299
@NP	Control	21299
@NP	scaffold	21308
@NP	B.	21325
@NP	Scaffold	21328
@NP	ADSCs and OECs	21349
@NP	the cell adipose-derived stem cells -LRB- ADSCs -RRB-	21386
@NP	the cell	21386
@NP	adipose-derived stem cells -LRB- ADSCs -RRB-	21395
@NP	adipose-derived stem cells	21395
@NP	ADSCs	21423
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	21435
@NP	olfactory ensheathing cells	21435
@NP	OECs	21464
@NP	7 days of in vitro incubation	21476
@NP	7 days	21476
@NP	incubation	21495
@NP	the scaffold	21509
@NP	Control -LRB- scaffold alone -RRB-	21523
@NP	Control	21523
@NP	scaffold	21532
@NP	C	21549
@NP	ADSCs stained with vimentin -LRB- D -RRB-	21553
@NP	ADSCs	21553
@NP	vimentin -LRB- D -RRB-	21572
@NP	vimentin	21572
@NP	D	21582
@NP	OECs stained with p75 -LRB- E -RRB-	21589
@NP	OECs stained with p75	21589
@NP	OECs	21589
@NP	p75	21607
@NP	E	21612
@NP	Fig. 3 .	21617
@NP	Fig.	21617
@NP	3	21622
@NP	Motor function improvement in response to the cell-loaded albumin scaffold .	21625
@NP	Motor function improvement	21625
@NP	response	21655
@NP	the cell-loaded albumin scaffold	21667
@NP	Plot	21701
@NP	the scores	21712
@NP	the modified BBB locomotor test	21735
@NP	a week	21772
@NP	90 days	21784
@NP	spinal cord injury and treatment	21798
@NP	spinal cord injury	21798
@NP	treatment	21821
@NP	all time points from 45 days post-injury	21835
@NP	all time points	21835
@NP	45 days	21856
@NP	the rate of improvement for G3	21877
@NP	the rate	21877
@NP	improvement for G3	21889
@NP	improvement	21889
@NP	G3	21905
@NP	the rate observed in G1 -LRB- * p < 0.05 -RRB-	21940
@NP	the rate	21940
@NP	G1	21961
@NP	p <	21966
@NP	p	21966
@NP	<	21967
@NP	0.05	21968
@NP	Values	21975
@NP	the means	21992
@NP	S.E.M.	22004
@NP	G1 : SCI-only .	22011
@NP	G1	22011
@NP	SCI-only	22015
@NP	G2 : SCI + scaffold .	22025
@NP	G2	22025
@NP	SCI + scaffold	22029
@NP	scaffold	22035
@NP	G3	22045
@NP	SCI with cell	22049
@NP	SCI	22049
@NP	cell	22058
@NP	scaffold	22070
@NP	Fig. 4 .	22081
@NP	Fig.	22081
@NP	4	22086
@NP	Hematoxylin/eosin -LRB- H&E -RRB- staining	22089
@NP	Hematoxylin/eosin -LRB- H&E -RRB-	22089
@NP	Hematoxylin/eosin	22089
@NP	H&E	22108
@NP	20 μm-thick longitudinal sections	22125
@NP	specimens from SCI-only group	22162
@NP	specimens	22162
@NP	SCI-only group	22177
@NP	G1 , A	22193
@NP	G1	22193
@NP	A	22196
@NP	SCI + scaffold -LRB- G2 , B -RRB-	22200
@NP	SCI + scaffold	22200
@NP	scaffold	22206
@NP	G2 , B	22216
@NP	G2	22216
@NP	B	22219
@NP	SCI with cell	22227
@NP	SCI	22227
@NP	cell	22236
@NP	scaffold group -LRB- G3 , C -RRB-	22248
@NP	scaffold group	22248
@NP	G3 , C	22264
@NP	G3	22264
@NP	C	22267
@NP	A.	22271
@NP	Histological appearance	22274
@NP	the central spinal cord cavity	22301
@NP	black arrow	22333
@NP	G1 , 90 days after SCI	22349
@NP	G1	22349
@NP	90 days after SCI	22353
@NP	90 days	22353
@NP	SCI	22367
@NP	B.	22372
@NP	Ninety days	22375
@NP	SCI and treatment	22393
@NP	SCI	22393
@NP	treatment	22401
@NP	the spaces at the site of injury	22412
@NP	the spaces	22412
@NP	the site of injury	22426
@NP	the site	22426
@NP	injury	22438
@NP	cells	22462
@NP	The albumin scaffold -LRB- red arrows -RRB-	22469
@NP	The albumin scaffold	22469
@NP	red arrows	22491
@NP	cells	22542
@NP	C.	22549
@NP	Ninety days	22552
@NP	SCI and treatment	22570
@NP	SCI	22570
@NP	treatment	22578
@NP	the spaces at the site of injury	22589
@NP	the spaces	22589
@NP	the site of injury	22603
@NP	the site	22603
@NP	injury	22615
@NP	ADSCs and OECs	22639
@NP	The albumin scaffold -LRB- red arrows -RRB-	22655
@NP	The albumin scaffold	22655
@NP	red arrows	22677
@NP	cells	22728
@NP	Fig. 5 .	22736
@NP	Fig.	22736
@NP	5	22741
@NP	Immunohistochemical staining	22744
@NP	central cord cavities in rats 90 days	22776
@NP	central cord cavities	22776
@NP	rats	22801
@NP	90 days	22806
@NP	SCI and treatment	22820
@NP	SCI	22820
@NP	treatment	22828
@NP	All sections 20 μm-thick longitudinal .	22839
@NP	All sections	22839
@NP	20 μm-thick longitudinal	22852
@NP	A-D	22878
@NP	SCIonly group -LRB- G1 -RRB- .	22883
@NP	SCIonly group -LRB- G1 -RRB-	22883
@NP	group -LRB- G1 -RRB-	22891
@NP	group	22891
@NP	G1	22898
@NP	E-H .	22903
@NP	SCI with cell	22908
@NP	SCI	22908
@NP	cell	22917
@NP	scaffold group -LRB- G3 -RRB-	22929
@NP	scaffold group	22929
@NP	G3	22945
@NP	the partially degraded scaffold in these images	22955
@NP	the partially degraded scaffold	22955
@NP	these images	22990
@NP	A , E.	23004
@NP	A	23004
@NP	E.	23007
@NP	Glial cells showing positivity for GFAP	23010
@NP	Glial cells	23010
@NP	positivity for GFAP	23030
@NP	positivity	23030
@NP	GFAP	23045
@NP	G1	23062
@NP	G3	23077
@NP	B , F.	23081
@NP	B	23081
@NP	F.	23084
@NP	Neuronal cells and fibers showing positivity for GAP-43	23087
@NP	Neuronal cells and fibers	23087
@NP	positivity for GAP-43	23121
@NP	positivity	23121
@NP	GAP-43	23136
@NP	the injury site within the neoformed tissue in G3	23158
@NP	the injury site	23158
@NP	the neoformed tissue in G3	23181
@NP	the neoformed tissue	23181
@NP	G3	23205
@NP	G1	23220
@NP	C , G.	23224
@NP	C	23224
@NP	G.	23227
@NP	Neuronal cells and fibers showing positivity for ß-III tubulin	23230
@NP	Neuronal cells and fibers	23230
@NP	positivity for ß-III tubulin	23264
@NP	positivity	23264
@NP	ß-III tubulin	23279
@NP	the injury site	23308
@NP	the neoformed tissue in G3	23331
@NP	the neoformed tissue	23331
@NP	G3	23355
@NP	Representative longitudinal sections	23359
@NP	positivity	23404
@NP	ß-III tubulin	23419
@NP	the zones immediately rostral and caudal to the lesion site in G1	23436
@NP	the zones	23436
@NP	the lesion site in G1	23480
@NP	the lesion site	23480
@NP	G1	23499
@NP	D , H.	23503
@NP	D	23503
@NP	H.	23506
@NP	Neurons and astroglial cells showing positivity for ß-galactosidase	23509
@NP	Neurons	23509
@NP	astroglial cells showing positivity for ß-galactosidase	23521
@NP	astroglial cells	23521
@NP	positivity for ß-galactosidase	23546
@NP	positivity	23546
@NP	ß-galactosidase	23561
@NP	the neoformed tissue in G3	23596
@NP	the neoformed tissue	23596
@NP	G3	23620
@NP	G1	23635
@NP	Microstructure of the scaffold and morphology of ADSCs and OECs	23640
@NP	Microstructure	23640
@NP	the scaffold and morphology of ADSCs and OECs	23658
@NP	the scaffold and morphology	23658
@NP	ADSCs and OECs	23689
@NP	the scaffold The surface features of the albumin scaffold were observed by SEM	23716
@NP	the scaffold	23716
@NP	The surface features of the albumin scaffold	23729
@NP	The surface features	23729
@NP	the albumin scaffold	23753
@NP	SEM	23791
@NP	ADSCs and OECs , recognized according to their morphology ,	23796
@NP	ADSCs and OECs	23796
@NP	their morphology	23836
@NP	the scaffold	23879
@NP	The structure of the three-dimensional scaffold	23893
@NP	The structure	23893
@NP	the three-dimensional scaffold	23910
@NP	Fig. 1A	23956
@NP	Pore diameter	23965
@NP	50 to 150 μm -LRB- Fig. 1 -RRB-	23991
@NP	50 to 150 μm	23991
@NP	Fig. 1	24005
@NP	an irregular sized and shaped sheet-like structure	24020
@NP	an irregular	24020
@NP	sheet-like structure	24050
@NP	all	24096
@NP	This	24127
@NP	suitable spaces for cells	24141
@NP	suitable spaces	24141
@NP	cells	24161
@NP	the scaffold	24180
@NP	SEM observation of the cells incubated in the scaffold for 7 days	24194
@NP	SEM observation	24194
@NP	the cells incubated in the scaffold for 7 days	24213
@NP	the cells	24213
@NP	the scaffold for 7 days	24236
@NP	the scaffold	24236
@NP	7 days	24253
@NP	OECs and ADSCs	24274
@NP	the scaffold -LRB- Fig. 1B -RRB-	24300
@NP	the scaffold	24300
@NP	Fig. 1B	24314
@NP	Survival and characteristics	24324
@NP	ADSCs and OECs	24356
@NP	the scaffold	24388
@NP	The effect of the scaffold on cell viability	24401
@NP	The effect	24401
@NP	the scaffold on cell viability	24415
@NP	the scaffold	24415
@NP	cell viability	24431
@NP	DNA staining	24464
@NP	DAPI	24483
@NP	the ADSCs and OECs for 7 days in the scaffold	24506
@NP	the ADSCs and OECs	24506
@NP	7 days in the scaffold	24529
@NP	7 days	24529
@NP	the scaffold	24539
@NP	almost all cell nuclei -LRB- 99 ± 3 % -RRB-	24553
@NP	almost all cell nuclei	24553
@NP	99 ± 3 %	24577
@NP	99	24577
@NP	± 3 %	24579
@NP	regular contours	24588
@NP	size , which is a characteristic of live cells -LRB- Fig. 2A , B -RRB-	24633
@NP	size	24633
@NP	a characteristic of live cells -LRB- Fig. 2A , B -RRB-	24648
@NP	a characteristic	24648
@NP	live cells -LRB- Fig. 2A , B -RRB-	24668
@NP	live cells	24668
@NP	Fig. 2A , B	24680
@NP	Fig. 2A	24680
@NP	B	24688
@NP	the cells	24698
@NP	immunohistochemical staining for vimentin and p75	24730
@NP	immunohistochemical staining	24730
@NP	vimentin and p75	24763
@NP	Almost all ADSCs	24781
@NP	vimentin positive -LRB- Fig. 2D -RRB-	24803
@NP	vimentin	24803
@NP	Fig. 2D	24822
@NP	OECs	24836
@NP	p75 -LRB- Fig. 2E -RRB-	24859
@NP	p75	24859
@NP	Fig. 2E	24864
@NP	Locomotor function The SCI model used	24874
@NP	Locomotor function	24874
@NP	The SCI model	24893
@NP	Demjen et al. , 2004	24943
@NP	Demjen	24943
@NP	et al.	24950
@NP	2004	24958
@NP	SCI	24973
@NP	symmetric paraplegia in the hind-limbs	24984
@NP	symmetric paraplegia	24984
@NP	the hind-limbs	25008
@NP	We	25024
@NP	multiple aspects	25038
@NP	spontaneous locomotion	25058
@NP	the modified BBB locomotor score -LRB- Basso et al. , 1995 -RRB-	25087
@NP	the modified BBB locomotor score	25087
@NP	Basso	25121
@NP	et al. , 1995	25127
@NP	et al.	25127
@NP	1995	25135
@NP	day one after injury	25145
@NP	day one	25145
@NP	injury	25159
@NP	no variations in scores	25167
@NP	no variations	25167
@NP	scores	25184
@NP	the three groups of animals	25211
@NP	the three groups	25211
@NP	animals	25231
@NP	all animals	25245
@NP	complete paraplegia and a lack of response	25267
@NP	complete paraplegia	25267
@NP	a lack of response	25291
@NP	a lack	25291
@NP	response	25301
@NP	sensory stimuli	25313
@NP	the hind-limbs	25332
@NP	scores	25348
@NP	0	25360
@NP	days 7 and 35 post-SCI	25372
@NP	days 7	25372
@NP	35 post-SCI	25383
@NP	the modified BBB score recorded for the SCI with cell	25396
@NP	the modified BBB score recorded	25396
@NP	the SCI with cell	25432
@NP	the SCI	25432
@NP	cell	25445
@NP	scaffold group -LRB- G3 -RRB-	25457
@NP	scaffold group	25457
@NP	G3	25473
@NP	the scores	25502
@NP	the control groups -LRB- G1 , SCI-only and G2 , SCI + scaffold -RRB-	25517
@NP	the control groups	25517
@NP	G1 , SCI-only and G2	25537
@NP	G1	25537
@NP	SCI-only	25541
@NP	G2	25554
@NP	SCI + scaffold	25558
@NP	SCI	25558
@NP	scaffold	25564
@NP	no case	25587
@NP	the difference	25599
@NP	clinical progress and locomotor function	25636
@NP	each time point from 45 days post-injury	25680
@NP	each time point	25680
@NP	45 days	25701
@NP	SCI	25750
@NP	cell seeded scaffold rats	25759
@NP	controls : 6.3 ± 1.8 in SCI-only	25798
@NP	controls	25798
@NP	6.3 ± 1.8 in SCI-only	25808
@NP	6.3 ± 1.8	25808
@NP	SCI-only	25821
@NP	5.4 ± 2.2 in SCI + scaffold -LRB- Fig. 3 -RRB-	25834
@NP	5.4 ± 2.2 in SCI	25834
@NP	5.4 ± 2.2	25834
@NP	SCI	25847
@NP	scaffold -LRB- Fig. 3 -RRB-	25853
@NP	scaffold	25853
@NP	Fig. 3	25863
@NP	45 days	25872
@NP	treatment	25886
@NP	SCI with cell	25897
@NP	SCI	25897
@NP	cell	25906
@NP	scaffold rats	25918
@NP	mean modified BBB scores	25939
@NP	8.3 ± 0.2 -LRB- the maximum score of 21.5 indicates no motor defects -RRB-	25967
@NP	8.3 ± 0.2	25967
@NP	the maximum score of 21.5	25976
@NP	the maximum score	25976
@NP	21.5	25997
@NP	no motor defects	26012
@NP	the scores	26043
@NP	the group	26077
@NP	score	26097
@NP	90 days of follow-up	26109
@NP	90 days	26109
@NP	follow-up	26120
@NP	9.1 ± 0.1	26134
@NP	Scores for the control groups	26143
@NP	Scores	26143
@NP	the control groups	26154
@NP	those recorded at 45 days : 5.7 ± 0.6	26189
@NP	those recorded at 45 days	26189
@NP	those	26189
@NP	45 days	26207
@NP	5.7 ± 0.6	26216
@NP	5.7 ±	26216
@NP	0.6	26220
@NP	4.3 ± 1.1 respectively -LRB- Fig. 3 -RRB-	26228
@NP	4.3	26228
@NP	± 1.1 respectively -LRB- Fig. 3 -RRB-	26231
@NP	± 1.1 respectively	26231
@NP	± 1.1	26231
@NP	Fig. 3	26250
@NP	figure 3	26277
@NP	no significant differences between control groups	26287
@NP	no significant differences	26287
@NP	control groups	26322
@NP	any of the treatment times	26354
@NP	any	26354
@NP	the treatment times	26361
@NP	overall locomotor recovery in the treatment group SCI with cell	26392
@NP	overall locomotor recovery	26392
@NP	the treatment group SCI	26422
@NP	cell	26451
@NP	scaffold	26463
@NP	the control groups	26505
@NP	the slopes of plots of scores against time	26541
@NP	the slopes	26541
@NP	plots of scores against time	26555
@NP	plots	26555
@NP	scores against time	26564
@NP	scores	26564
@NP	time	26579
@NP	Histological analysis	26585
@NP	the course of spinal injury	26617
@NP	the course	26617
@NP	spinal injury	26631
@NP	the process of nervous tissue regeneration in vivo	26649
@NP	the process	26649
@NP	nervous tissue regeneration in vivo	26664
@NP	nervous tissue regeneration	26664
@NP	vivo	26695
@NP	histological studies	26701
@NP	all groups of animals	26740
@NP	all groups	26740
@NP	animals	26754
@NP	their sacrifice 90 days post-injury	26768
@NP	their sacrifice	26768
@NP	90 days	26784
@NP	H&E staining	26813
@NP	it	26826
@NP	SCI-only	26845
@NP	the spinal cord central cavity	26859
@NP	many areas empty of cells	26894
@NP	many areas	26894
@NP	cells	26914
@NP	some zones	26930
@NP	bundles of tissue	26967
@NP	bundles	26967
@NP	tissue	26978
@NP	there	26990
@NP	no evidence of significant tissue regeneration -LRB- Fig. 4A -RRB-	27000
@NP	no evidence	27000
@NP	significant tissue regeneration -LRB- Fig. 4A -RRB-	27015
@NP	significant tissue regeneration	27015
@NP	Fig. 4A	27048
@NP	contrast	27061
@NP	SCI + scaffold -LRB- Fig. 4B -RRB-	27074
@NP	SCI	27074
@NP	scaffold	27080
@NP	Fig. 4B	27090
@NP	SCI with cell	27107
@NP	SCI	27107
@NP	cell	27116
@NP	scaffold group	27128
@NP	Fig. 4C	27144
@NP	the cord central cavity	27153
@NP	cells 90 days post-injury	27204
@NP	cells	27204
@NP	90 days	27210
@NP	A visible reduction in the volume of residual scaffold	27231
@NP	A visible reduction	27231
@NP	the volume of residual scaffold	27254
@NP	the volume	27254
@NP	residual scaffold	27268
@NP	the	27302
@NP	period	27314
@NP	reabsorption of the scaffold and replacement with new tissue	27333
@NP	reabsorption	27333
@NP	the scaffold and replacement with new tissue	27349
@NP	the scaffold and replacement	27349
@NP	new tissue	27383
@NP	Sirius red	27395
@NP	the extent of scar tissue formation	27427
@NP	the extent	27427
@NP	scar tissue formation	27441
@NP	the site of injury	27470
@NP	the site	27470
@NP	injury	27482
@NP	collagen	27493
@NP	all animal groups at 90 days post-injury -LRB- see Table 1 -RRB-	27514
@NP	all animal groups	27514
@NP	90 days post-injury -LRB- see Table 1 -RRB-	27535
@NP	90 days post-injury	27535
@NP	Table 1	27560
@NP	This	27570
@NP	the motor improvement observed in SCI with cell	27589
@NP	the motor improvement	27589
@NP	SCI	27623
@NP	cell	27632
@NP	scaffold group	27644
@NP	collagen scar inhibition	27678
@NP	Immunohistochemical analysis	27704
@NP	it	27738
@NP	the presence of scaffold plus cells	27767
@NP	the presence	27767
@NP	scaffold plus cells	27783
@NP	scaffold	27783
@NP	cells	27797
@NP	collagen synthesis	27819
@NP	SCI	27844
@NP	we	27849
@NP	the classic concept of the formation of a glial scar	27861
@NP	the classic concept	27861
@NP	the formation of a glial scar	27884
@NP	the formation	27884
@NP	a glial scar	27901
@NP	the injured spinal cord tissue	27917
@NP	an antibody against the astrocyte marker GFAP	27954
@NP	an antibody	27954
@NP	the astrocyte marker GFAP	27974
@NP	The results of this analysis	28001
@NP	The results	28001
@NP	this analysis	28016
@NP	rats in group SCI with cell	28044
@NP	rats	28044
@NP	group SCI with cell	28052
@NP	group SCI	28052
@NP	cell	28067
@NP	scaffold 90 days post-injury	28079
@NP	scaffold	28079
@NP	90 days	28088
@NP	GFAPnegative cells	28115
@NP	the cord cavity and close	28142
@NP	the injury site -LRB- rostral and caudal -RRB- -LRB- Fig. 5E -RRB-	28171
@NP	the injury site -LRB- rostral and caudal -RRB-	28171
@NP	the injury site	28171
@NP	rostral and caudal	28188
@NP	rostral	28188
@NP	caudal	28200
@NP	Fig. 5E	28209
@NP	SCIonly rats	28227
@NP	sites immediately -LRB- rostral and caudal -RRB-	28262
@NP	sites immediately	28262
@NP	sites	28262
@NP	rostral and caudal	28281
@NP	rostral	28281
@NP	caudal	28293
@NP	the point	28309
@NP	injury	28322
@NP	the presence of glial scar in this control group -LRB- Fig. 5A -RRB-	28345
@NP	the presence	28345
@NP	glial scar in this control group -LRB- Fig. 5A -RRB-	28361
@NP	glial scar	28361
@NP	this control group -LRB- Fig. 5A -RRB-	28375
@NP	this control group	28375
@NP	Fig. 5A	28395
@NP	contrast	28408
@NP	cord cells in SCI + scaffold	28418
@NP	cord cells	28418
@NP	SCI + scaffold	28432
@NP	SCI	28432
@NP	scaffold	28438
@NP	GFAP-immunostaining at the lesion site -LRB- images not shown -RRB-	28465
@NP	GFAP-immunostaining	28465
@NP	the lesion site	28488
@NP	images not shown	28505
@NP	images	28505
@NP	These observations	28524
@NP	the scaffold	28556
@NP	glial scar formation	28595
@NP	the scaffold plus cells	28625
@NP	the scaffold	28625
@NP	cells	28643
@NP	this glial scar	28665
@NP	the origin of newly formed tissue	28692
@NP	the origin	28692
@NP	newly formed tissue	28706
@NP	the spinal cord cavities of the treatment groups	28729
@NP	the spinal cord cavities	28729
@NP	the treatment groups	28757
@NP	we	28779
@NP	different specific antibodies	28787
@NP	the newly formed tissue	28846
@NP	a bridge that permitted the passage of ascending and descending axons	28883
@NP	a bridge	28883
@NP	the passage of ascending and descending axons	28907
@NP	the passage	28907
@NP	axons	28947
@NP	we	28954
@NP	axons	28968
@NP	tyrosine hydroxylase , neurofilament 200 , dopamine ßhydroxylase and GAP-43	28985
@NP	tyrosine hydroxylase	28985
@NP	neurofilament 200	29007
@NP	dopamine ßhydroxylase	29026
@NP	GAP-43	29052
@NP	possible components of regeneration -LRB- see Table 1 -RRB-	29063
@NP	possible components	29063
@NP	regeneration	29086
@NP	Table 1	29104
@NP	SCI with cell	29120
@NP	SCI	29120
@NP	cell	29129
@NP	scaffold	29141
@NP	positive immunostaining	29157
@NP	antibodies	29185
@NP	tyrosine hydroxylase and neurofilament 200 inside	29204
@NP	tyrosine hydroxylase	29204
@NP	neurofilament 200 inside	29229
@NP	the scaffold -LRB- images not shown -RRB-	29265
@NP	the scaffold	29265
@NP	images not shown	29279
@NP	images	29279
@NP	cells in the cords of the SCI with cell	29309
@NP	cells	29309
@NP	the cords of the SCI with cell	29318
@NP	the cords	29318
@NP	the SCI with cell	29331
@NP	the SCI	29331
@NP	cell	29344
@NP	scaffold animals	29356
@NP	GAP-43 positive rostral to the scaffold -LRB- injury site -RRB-	29378
@NP	GAP-43 positive rostral	29378
@NP	the scaffold -LRB- injury site -RRB-	29405
@NP	the scaffold	29405
@NP	injury site	29419
@NP	immunopositive staining	29439
@NP	the space where the initial injury took place	29466
@NP	the space	29466
@NP	the initial injury	29482
@NP	place	29506
@NP	the cell-loaded scaffolds	29535
@NP	the newly formed tissue	29576
@NP	neurons or neuronal elements	29610
@NP	neurons	29610
@NP	neuronal elements	29621
@NP	SCI-only cords	29640
@NP	tyrosine hydroxylase , neurofilament 200 , and GAP-43	29673
@NP	tyrosine hydroxylase	29673
@NP	neurofilament 200	29695
@NP	GAP-43	29718
@NP	rostral	29730
@NP	caudal zones	29741
@NP	the injury site -LRB- Fig. 5B -RRB-	29765
@NP	the injury site	29765
@NP	Fig. 5B	29782
@NP	contrast	29795
@NP	cord cells in SCI + scaffold animals	29805
@NP	cord cells	29805
@NP	SCI + scaffold animals	29819
@NP	SCI	29819
@NP	scaffold animals	29825
@NP	very few neurofilament 200 , tyrosine hydroxylase , and GAP-43 positive fibers	29852
@NP	very few neurofilament 200	29852
@NP	tyrosine hydroxylase	29880
@NP	GAP-43 positive fibers	29906
@NP	the injury site -LRB- images not shown -RRB-	29932
@NP	the injury site	29932
@NP	images not shown	29949
@NP	images	29949
@NP	all groups	29971
@NP	cord cells	29983
@NP	dopamine ß-hydroxylase negative at the injury site -LRB- images not shown -RRB-	29999
@NP	dopamine ß-hydroxylase	29999
@NP	the injury site -LRB- images not shown -RRB-	30034
@NP	the injury site	30034
@NP	images not shown	30051
@NP	images	30051
@NP	the presence of neural and astroglial cells	30090
@NP	the presence	30090
@NP	neural and astroglial cells	30106
@NP	the site of injury	30137
@NP	the site	30137
@NP	injury	30149
@NP	we	30157
@NP	neurons	30174
@NP	ß-III tubulin -LRB- adult neurons -RRB- , GAP	30193
@NP	ß-III tubulin	30193
@NP	adult neurons	30208
@NP	GAP	30224
@NP	43 -LRB- neurons observed during developmental growth -RRB-	30229
@NP	43	30229
@NP	neurons observed during developmental growth	30233
@NP	neurons	30233
@NP	developmental growth	30257
@NP	neurons and astroglial cells expressing ß-galactosidase -LRB- see Table 1 -RRB-	30283
@NP	neurons	30283
@NP	astroglial cells expressing ß-galactosidase -LRB- see Table 1 -RRB-	30295
@NP	astroglial cells expressing ß-galactosidase	30295
@NP	astroglial cells	30295
@NP	ß-galactosidase	30323
@NP	Table 1	30344
@NP	Cord cells in all the treatment groups	30354
@NP	Cord cells	30354
@NP	all the treatment groups	30368
@NP	immunopositive staining	30400
@NP	the ß-III tubulin antibody	30428
@NP	there	30465
@NP	few ß-III	30481
@NP	tubulinpositive cells in SCI-only and SCI	30491
@NP	tubulinpositive cells	30491
@NP	SCI-only and SCI	30516
@NP	scaffold groups compared to the SCI with cell	30535
@NP	scaffold groups	30535
@NP	the SCI with cell	30563
@NP	the SCI	30563
@NP	cell	30576
@NP	scaffold group -LRB- Fig. 5C , G -RRB-	30588
@NP	scaffold group	30588
@NP	Fig. 5C , G	30604
@NP	Fig. 5C	30604
@NP	G	30612
@NP	the cords in SCI + scaffold and SCI with cell	30626
@NP	the cords	30626
@NP	SCI + scaffold and SCI with cell	30639
@NP	SCI + scaffold	30639
@NP	scaffold	30645
@NP	SCI with cell	30658
@NP	SCI	30658
@NP	cell	30667
@NP	scaffold animals	30679
@NP	positive immunostaining	30703
@NP	the GAP-43 antibody	30731
@NP	the injury site	30754
@NP	their ß-III tubulin staining pattern	30782
@NP	cord cells in SCI-only animals	30820
@NP	cord cells	30820
@NP	SCI-only animals	30834
@NP	Fig. 5B , F	30873
@NP	Cord cells in SCI with cell	30885
@NP	Cord cells	30885
@NP	SCI with cell	30899
@NP	SCI	30899
@NP	cell	30908
@NP	scaffold group	30920
@NP	the control groups	30992
@NP	this antibody -LRB- Fig. 5D , H -RRB-	31041
@NP	this antibody	31041
@NP	Fig. 5D , H	31056
@NP	Fig. 5D	31056
@NP	H	31064
@NP	Discussion Recent research efforts	31069
@NP	the field of SCI therapy	31107
@NP	the field	31107
@NP	SCI therapy	31120
@NP	new biodegradable scaffolds	31159
@NP	a permissive and stimulating environment	31197
@NP	nerve regeneration -LRB- Madigan et al. , 2009 ; Straley et al. , 2010 -RRB-	31242
@NP	nerve regeneration	31242
@NP	Madigan	31262
@NP	et al. , 2009 ; Straley et al. , 2010	31270
@NP	et al.	31270
@NP	2009 ; Straley et al.	31278
@NP	2009	31278
@NP	Straley et al.	31284
@NP	Straley	31284
@NP	et al.	31292
@NP	2010	31300
@NP	The main goal of the present study	31307
@NP	The main goal	31307
@NP	the present study	31324
@NP	the performance	31356
@NP	a solid human serum-derived scaffold developed by our research group	31375
@NP	a solid human serum-derived scaffold	31375
@NP	our research group	31425
@NP	a previous study	31448
@NP	we	31466
@NP	the use of this albumin scaffold	31478
@NP	the use	31478
@NP	this albumin scaffold	31489
@NP	bone defects	31521
@NP	osteoblasts in a rat model -LRB- Gallego et al. , 2010 -RRB-	31549
@NP	osteoblasts	31549
@NP	a rat model -LRB- Gallego et al. , 2010 -RRB-	31564
@NP	a rat model	31564
@NP	Gallego	31577
@NP	et al. , 2010	31585
@NP	et al.	31585
@NP	2010	31593
@NP	Similar tissue engineered implants	31600
@NP	Similar tissue	31600
@NP	implants	31626
@NP	the problem	31649
@NP	the toxicity of the crosslinking agent glutaraldehyde	31666
@NP	the toxicity	31666
@NP	the crosslinking agent glutaraldehyde	31682
@NP	cell culture	31736
@NP	The lyophilization step after crosslinking incorporated in our technique	31750
@NP	The lyophilization step	31750
@NP	our technique	31809
@NP	the toxic properties of this agent -LRB- Gallego et al. , 2010 -RRB-	31841
@NP	the toxic properties	31841
@NP	this agent -LRB- Gallego et al. , 2010 -RRB-	31865
@NP	this agent	31865
@NP	Gallego	31877
@NP	et al. , 2010	31885
@NP	et al.	31885
@NP	2010	31893
@NP	The findings of this study	31900
@NP	The findings	31900
@NP	this study	31916
@NP	the scaffold developed	31940
@NP	the scaffold	31940
@NP	an appropriate substrate for nerve tissue regeneration	31966
@NP	an appropriate substrate	31966
@NP	nerve tissue regeneration	31995
@NP	an autologous scaffold	32052
@NP	The scaffold	32076
@NP	the advantage that it is easy and nonexpensive to produce	32098
@NP	the advantage	32098
@NP	it	32117
@NP	Pore structure	32157
@NP	scaffolds	32207
@NP	tissue engineering	32221
@NP	High porosity and wellconnected	32241
@NP	High porosity	32241
@NP	wellconnected	32259
@NP	good mass transfer properties and increase cell viability	32286
@NP	good mass transfer properties	32286
@NP	increase cell viability	32320
@NP	A porous scaffold microstructure with minimal pore size	32345
@NP	A porous scaffold microstructure	32345
@NP	minimal pore size	32383
@NP	tissue ingrowth -LRB- Zeltinger et al. , 2001 -RRB-	32430
@NP	tissue ingrowth	32430
@NP	Zeltinger	32447
@NP	et al. , 2001	32457
@NP	et al.	32457
@NP	2001	32465
@NP	The pore size of our scaffold	32472
@NP	The pore size	32472
@NP	our scaffold	32489
@NP	50 to 150 μm	32538
@NP	a larger pore size	32556
@NP	longitudinal sections	32587
@NP	cross sections of scaffold	32614
@NP	cross sections	32614
@NP	scaffold	32632
@NP	These	32642
@NP	shape	32676
@NP	a suitable architecture	32720
@NP	cell penetration	32748
@NP	the three-dimensional structure of the scaffold used in our study	32772
@NP	the three-dimensional structure	32772
@NP	the scaffold used in our study	32807
@NP	the scaffold	32807
@NP	our study	32828
@NP	a suitable framework	32847
@NP	guiding axon regeneration across its large gaps or cavities	32872
@NP	guiding axon regeneration	32872
@NP	its large gaps or cavities	32905
@NP	sufficient space	32945
@NP	ADSC neurotransdifferentiation	32966
@NP	Various types of cell	32998
@NP	Various types	32998
@NP	cell	33015
@NP	cell therapy	33038
@NP	SCI	33065
@NP	Schwann cells	33080
@NP	Ramon	33095
@NP	Cueto	33102
@NP	et al. , 2000	33108
@NP	et al.	33108
@NP	2000	33116
@NP	Verdu et al. , 2003	33122
@NP	Verdu	33122
@NP	et al. , 2003	33128
@NP	et al.	33128
@NP	2003	33136
@NP	Garcia-Alias et al. , 2004 -RRB-	33142
@NP	Garcia-Alias	33142
@NP	et al.	33155
@NP	2004	33163
@NP	bone marrow stem cells -LRB- BMSCs -RRB- -LRB- Chopp and Li , 2002	33173
@NP	bone marrow stem cells -LRB- BMSCs -RRB-	33173
@NP	bone marrow stem cells	33173
@NP	BMSCs	33197
@NP	Chopp and Li	33205
@NP	2002	33219
@NP	Zurita and Vaquero , 2006	33225
@NP	Zurita and Vaquero	33225
@NP	2006	33245
@NP	harvesting bone marrow -LRB- BM -RRB-	33258
@NP	harvesting bone marrow	33258
@NP	BM	33282
@NP	a highly invasive procedure	33289
@NP	researchers	33318
@NP	the use of adipose tissue	33345
@NP	the use	33345
@NP	adipose tissue	33356
@NP	an alternative rich source of MSC	33374
@NP	an alternative rich source	33374
@NP	MSC	33404
@NP	effect	33412
@NP	ADSCs	33420
@NP	numerous properties	33431
@NP	them	33461
@NP	ideal candidates for cell transplant therapy	33466
@NP	ideal candidates	33466
@NP	cell transplant therapy	33487
@NP	SCI	33517
@NP	These cells	33522
@NP	characteristics with BMSCs	33540
@NP	characteristics	33540
@NP	BMSCs	33561
@NP	immune rejection -LRB- Wang et al. , 2007 -RRB-	33587
@NP	immune rejection	33587
@NP	Wang	33605
@NP	et al. , 2007	33610
@NP	et al.	33610
@NP	2007	33618
@NP	they	33629
@NP	the advantage	33639
@NP	they	33658
@NP	subcutaneous adipose tissue	33691
@NP	Zuk et al. , 2001 ; Yarak and Okamoto , 2010	33741
@NP	Zuk	33741
@NP	et al. , 2001 ; Yarak and Okamoto , 2010	33745
@NP	et al. , 2001	33745
@NP	et al.	33745
@NP	2001	33753
@NP	Yarak and Okamoto , 2010	33759
@NP	Yarak and Okamoto	33759
@NP	2010	33778
@NP	contrast	33788
@NP	OECs	33798
@NP	the olfactory bulb and olfactory lamina propria	33821
@NP	the limitation of the scarce availability of functional cells	33874
@NP	the limitation	33874
@NP	the scarce availability of functional cells	33892
@NP	the scarce availability	33892
@NP	functional cells	33919
@NP	Wang et al. -LRB- 2007 -RRB-	33937
@NP	Wang et al.	33937
@NP	Wang	33937
@NP	et al.	33942
@NP	2007	33950
@NP	OECs	33970
@NP	a variety	33983
@NP	growth factors	33996
@NP	the neural differentiation of ADSCs in three-dimensional scaffolds	34024
@NP	the neural differentiation	34024
@NP	ADSCs in three-dimensional scaffolds	34054
@NP	ADSCs	34054
@NP	three-dimensional scaffolds	34063
@NP	the complementary biological properties of OECs and ADSCs	34107
@NP	the complementary biological properties	34107
@NP	OECs and ADSCs	34150
@NP	we	34166
@NP	both cell types	34185
@NP	our rat model of SCI	34204
@NP	our rat model	34204
@NP	SCI	34221
@NP	Our	34226
@NP	tests	34239
@NP	both OECs and ADSCs	34259
@NP	OECs	34264
@NP	ADSCs	34273
@NP	their viability and phenotype	34290
@NP	seed the scaffold	34333
@NP	seed	34333
@NP	the scaffold	34338
@NP	7 days in the scaffolds	34375
@NP	7 days	34375
@NP	the scaffolds	34385
@NP	these	34400
@NP	the injured rats	34424
@NP	Wang et al.	34455
@NP	Wang	34455
@NP	et al.	34460
@NP	Wang et al. , 2007 -RRB- , in vivo neuro-differentiation	34468
@NP	Wang et al. , 2007 -RRB- , in vivo	34468
@NP	Wang et al. , 2007 -RRB-	34468
@NP	Wang	34468
@NP	et al.	34473
@NP	2007	34481
@NP	vivo	34491
@NP	neuro-differentiation	34496
@NP	place	34524
@NP	20-30 days	34530
@NP	The neuro-differentiation of ADSCs and their survival and migration from the	34556
@NP	The neuro-differentiation	34556
@NP	ADSCs and their survival and migration from the	34585
@NP	ADSCs	34585
@NP	their survival and migration from the	34595
@NP	their survival and migration	34595
@NP	the	34629
@NP	site	34641
@NP	future studies	34678
@NP	Our functional in vivo results	34694
@NP	Our functional	34694
@NP	vivo results	34712
@NP	modified BBB	34741
@NP	scores	34762
@NP	Basso	34770
@NP	et al. , 1995	34776
@NP	et al.	34776
@NP	1995	34784
@NP	our three experimental groups	34802
@NP	90 days	34835
@NP	the motor recovery observed in SCI with cell	34862
@NP	the motor recovery	34862
@NP	SCI	34893
@NP	cell	34902
@NP	scaffold group -LRB- G3 -RRB- over that recorded in controls at this time point	34914
@NP	scaffold group -LRB- G3 -RRB-	34914
@NP	scaffold group	34914
@NP	G3	34930
@NP	that recorded in controls at this time point	34939
@NP	that	34939
@NP	controls at this time point	34956
@NP	controls	34956
@NP	this time point	34968
@NP	Other authors -LRB- Ramon-Cueto et al. , 2000 ; Lu et al. , 2002 -RRB-	35001
@NP	Other authors	35001
@NP	Ramon-Cueto	35016
@NP	et al. , 2000 ; Lu et al. , 2002	35028
@NP	et al.	35028
@NP	2000 ; Lu et al.	35036
@NP	2000	35036
@NP	Lu et al.	35042
@NP	Lu	35042
@NP	et al.	35045
@NP	2002	35053
@NP	the transplantation	35078
@NP	OECs or BMSCs into injured spinal cord tissue in rats with paraplegia	35101
@NP	OECs or BMSCs	35101
@NP	injured spinal cord tissue in rats with paraplegia	35120
@NP	injured spinal cord tissue	35120
@NP	rats with paraplegia	35150
@NP	rats	35150
@NP	paraplegia	35160
@NP	a clear functional recovery	35180
@NP	a few weeks	35220
@NP	transplantation -LRB- Vaquero et al. , 2006 -RRB-	35238
@NP	transplantation	35238
@NP	Vaquero	35255
@NP	et al. , 2006	35263
@NP	et al.	35263
@NP	2006	35271
@NP	Our SCI with cell	35278
@NP	Our SCI	35278
@NP	cell	35291
@NP	scaffold animals	35303
@NP	improved locomotor scores early after SCI -LRB- up to 21 days postinjury -RRB-	35327
@NP	improved locomotor scores	35327
@NP	SCI -LRB- up to 21 days postinjury -RRB-	35365
@NP	SCI	35365
@NP	up to 21 days	35370
@NP	controls -LRB- SCI-only , SCI + scaffold -RRB-	35401
@NP	controls	35401
@NP	SCI-only , SCI + scaffold	35411
@NP	SCI-only	35411
@NP	SCI + scaffold	35421
@NP	scaffold	35427
@NP	around 9 -LRB- from 45 days post-injury -RRB-	35464
@NP	around 9	35464
@NP	45 days	35479
@NP	This score	35501
@NP	plantar placement	35522
@NP	the paw	35543
@NP	weight support in stance only or occasional , frequent or consistent weight	35556
@NP	weight support in stance only	35556
@NP	weight support	35556
@NP	stance only	35574
@NP	occasional , frequent or consistent weight	35589
@NP	dorsal stepping and no plantar stepping	35641
@NP	dorsal stepping	35641
@NP	dorsal	35641
@NP	no plantar stepping	35661
@NP	no plantar	35661
@NP	contrast	35685
@NP	SCI-only group , in which injured animals were left untreated ,	35695
@NP	SCI-only group	35695
@NP	injured animals	35720
@NP	stable mean modified BBB scores of approximately 5 , and SCI + scaffold group	35771
@NP	stable mean	35771
@NP	BBB scores of approximately 5 , and SCI + scaffold group	35792
@NP	BBB scores	35792
@NP	approximately 5 , and SCI + scaffold group	35806
@NP	approximately 5	35806
@NP	SCI + scaffold group	35827
@NP	scaffold group	35833
@NP	a slightly lower score -LRB- approximately 4 -RRB-	35857
@NP	a slightly lower score	35857
@NP	approximately 4	35881
@NP	These results	35899
@NP	those	35933
@NP	several studies	35942
@NP	Ramon-Cueto et al. , 1998 ; Deng et al. , 2006 ; Zurita et al. , 2008	35959
@NP	Ramon-Cueto	35959
@NP	et al. , 1998 ; Deng et al. , 2006 ; Zurita et al. , 2008	35971
@NP	et al. , 1998	35971
@NP	et al.	35971
@NP	1998	35979
@NP	Deng et al. , 2006	35985
@NP	Deng	35985
@NP	et al. , 2006	35990
@NP	et al.	35990
@NP	2006	35998
@NP	Zurita et al. , 2008	36004
@NP	Zurita	36004
@NP	et al. , 2008	36011
@NP	et al.	36011
@NP	2008	36019
@NP	transplantation of either BMSCs or OECs	36034
@NP	transplantation	36034
@NP	either BMSCs or OECs	36053
@NP	functional recovery	36101
@NP	SCI	36127
@NP	Deng et al. , 2008	36142
@NP	Deng et al.	36142
@NP	Deng	36142
@NP	et al.	36147
@NP	2008	36155
@NP	co-transplantation of OECs and BMSCs	36175
@NP	co-transplantation	36175
@NP	OECs and BMSCs	36197
@NP	the functional recovery of SCI in rats , probably	36245
@NP	the functional recovery	36245
@NP	SCI	36272
@NP	rats	36279
@NP	such a way	36297
@NP	OECs	36313
@NP	the neuronal differentiation of implanted BMSCs	36343
@NP	the neuronal differentiation	36343
@NP	implanted BMSCs	36375
@NP	possible mechanisms	36405
@NP	the observed functional recovery	36436
@NP	we	36470
@NP	several histology and immunohistochemistry techniques	36478
@NP	histological studies on our SCI-untreated control animals	36539
@NP	histological studies	36539
@NP	our SCI-untreated control animals	36563
@NP	the persistence of the typical post-traumatic spinal cord cavity	36606
@NP	the persistence	36606
@NP	the typical post-traumatic spinal cord cavity	36625
@NP	90 days	36671
@NP	injury	36685
@NP	Zurita and Vaquero	36693
@NP	2006	36713
@NP	contrast	36723
@NP	the injured animals	36736
@NP	cell seeded scaffold -LRB- G3 -RRB- or a SCI + scaffold -LRB- G2 -RRB-	36769
@NP	cell	36769
@NP	scaffold -LRB- G3 -RRB- or a SCI + scaffold -LRB- G2 -RRB-	36781
@NP	scaffold -LRB- G3 -RRB- or a SCI	36781
@NP	scaffold -LRB- G3 -RRB-	36781
@NP	scaffold	36781
@NP	G3	36791
@NP	a SCI	36798
@NP	scaffold -LRB- G2 -RRB-	36806
@NP	scaffold	36806
@NP	G2	36816
@NP	the post-SCI cavity	36821
@NP	cells	36868
@NP	This	36875
@NP	the cells implanted within the scaffold	36894
@NP	the cells	36894
@NP	the scaffold	36921
@NP	the spinal cord cavity	36957
@NP	new nervous tissue	36989
@NP	a bridge for the passage of descending axons	37026
@NP	a bridge	37026
@NP	the passage of descending axons	37039
@NP	the passage	37039
@NP	descending axons	37054
@NP	this idea	37081
@NP	the infilled spinal cord cavity observed after the implant of the scaffold alone	37108
@NP	the	37108
@NP	spinal cord cavity observed after the implant of the scaffold alone	37121
@NP	spinal cord cavity	37121
@NP	the	37155
@NP	the scaffold	37170
@NP	A possible explanation	37190
@NP	call-cells	37221
@NP	this	37240
@NP	the lesion site in response	37261
@NP	the lesion site	37261
@NP	response	37280
@NP	injury	37292
@NP	effect	37303
@NP	it	37311
@NP	these new cells	37328
@NP	-LRB- call-cells -RRB-	37353
@NP	the spinal cord	37369
@NP	the damaged area	37400
@NP	it	37424
@NP	they	37438
@NP	injured cells -LRB- McDonald and Becker , 2003 -RRB-	37451
@NP	injured cells	37451
@NP	McDonald and Becker , 2003	37466
@NP	McDonald	37466
@NP	Becker , 2003	37479
@NP	Becker	37479
@NP	2003	37487
@NP	the new scaffold	37500
@NP	a good support for these call-cells	37530
@NP	a good support	37530
@NP	these call-cells	37549
@NP	The classic concept	37567
@NP	scar formation -LRB- connective tissue scar or glial scar -RRB-	37592
@NP	scar formation	37592
@NP	connective tissue scar or glial scar	37608
@NP	connective tissue scar	37608
@NP	glial scar	37634
@NP	the injured spinal cord tissue	37649
@NP	the passage of regenerated axons	37693
@NP	the passage	37693
@NP	regenerated axons	37708
@NP	one extreme of the lesion	37731
@NP	one extreme	37731
@NP	the lesion	37746
@NP	the other	37760
@NP	90 days	37825
@NP	scaffold	37839
@NP	this time point	37860
@NP	fibrous tissue identified by Sirius red staining	37877
@NP	fibrous tissue	37877
@NP	Sirius red staining	37906
@NP	the margins of the spinal cord cavity in all the treatment groups	37943
@NP	the margins	37943
@NP	the spinal cord cavity in all the treatment groups	37958
@NP	the spinal cord cavity	37958
@NP	all the treatment groups	37984
@NP	immunostaining for GFAP in SCI + scaffold and SCI with cell	38019
@NP	immunostaining	38019
@NP	GFAP in SCI + scaffold and SCI with cell	38038
@NP	GFAP	38038
@NP	SCI + scaffold and SCI with cell	38046
@NP	SCI + scaffold	38046
@NP	scaffold	38052
@NP	SCI with cell	38065
@NP	SCI	38065
@NP	cell	38074
@NP	scaffold groups	38086
@NP	the presence of astrocytes at the injury site or caudal or rostral	38119
@NP	the presence	38119
@NP	astrocytes at the injury site or caudal or rostral	38135
@NP	astrocytes	38135
@NP	the injury site or caudal or rostral	38149
@NP	this point 3 months	38189
@NP	this point	38189
@NP	3 months	38200
@NP	SCI	38215
@NP	this time point	38223
@NP	the tissue repair process	38240
@NP	a steady state	38286
@NP	contrast	38305
@NP	large populations of GFAPpositive astrocytes	38315
@NP	large populations	38315
@NP	GFAPpositive astrocytes	38336
@NP	the injury site and caudal and rostral	38377
@NP	this site in SCI-only	38419
@NP	this site	38419
@NP	SCI-only	38432
@NP	SCI	38447
@NP	Some authors	38452
@NP	downregulation of GFAP	38479
@NP	downregulation	38479
@NP	GFAP	38497
@NP	reactive astrocytes	38505
@NP	OECs transplanted into lesioned spinal cords -LRB- Verdu et al. , 2001 -RRB-	38536
@NP	OECs	38536
@NP	lesioned spinal cords -LRB- Verdu et al. , 2001 -RRB-	38559
@NP	lesioned spinal cords	38559
@NP	Verdu	38582
@NP	et al. , 2001	38588
@NP	et al.	38588
@NP	2001	38596
@NP	The absence	38603
@NP	glial scar tissue observed in the spinal cords of the scaffold-treated animals	38618
@NP	glial scar tissue	38618
@NP	the spinal cords of the scaffold-treated animals	38648
@NP	the spinal cords	38648
@NP	the scaffold-treated animals	38668
@NP	the albumin scaffold	38711
@NP	reactive astrocytes	38770
@NP	their reactivity	38800
@NP	a protective environment	38830
@NP	Animals in SCI with cell	38856
@NP	Animals	38856
@NP	SCI with cell	38867
@NP	SCI	38867
@NP	cell	38876
@NP	scaffold group	38888
@NP	immunopositive staining	38910
@NP	antibodies against neural and astroglial cells	38938
@NP	antibodies	38938
@NP	neural and astroglial cells	38957
@NP	the injury site	38988
@NP	the newly formed tissue	39021
@NP	neurons and glial cells	39054
@NP	neurons	39054
@NP	glial cells	39066
@NP	this neotissue	39089
@NP	SCI	39119
@NP	the spinal cord cavity	39146
@NP	the passage of descending and ascending neurons	39179
@NP	the passage	39179
@NP	neurons	39219
@NP	the specific antibodies used	39243
@NP	the specific antibodies	39243
@NP	SCI-only group	39273
@NP	ß-III tubulin-positive fibers	39295
@NP	the slight locomotor recovery observed in control rats	39341
@NP	the slight locomotor recovery	39341
@NP	control rats	39383
@NP	the neoformation of the axons detected	39419
@NP	the neoformation	39419
@NP	the axons detected	39439
@NP	the axons	39439
@NP	the scaffold	39468
@NP	functional recovery	39513
@NP	it	39534
@NP	the ingrowth of a variety of cell types	39569
@NP	the ingrowth	39569
@NP	a variety of cell types	39585
@NP	a variety	39585
@NP	cell types	39598
@NP	glial scar inhibition	39626
@NP	a support for callcells	39670
@NP	a support	39670
@NP	callcells	39684
@NP	These results	39695
@NP	the scaffold	39717
@NP	itself	39730
@NP	an adequate environment for both the survival and differentiation , at least	39746
@NP	an adequate environment for both the survival and differentiation	39746
@NP	an adequate environment	39746
@NP	both the survival and differentiation	39774
@NP	these call-cells that fill the cord cavity	39833
@NP	these call-cells	39833
@NP	the cord cavity	39860
@NP	it	39885
@NP	most of these newborn cells -LRB- call-cells -RRB-	39911
@NP	most	39911
@NP	these newborn cells -LRB- call-cells -RRB-	39919
@NP	these newborn cells	39919
@NP	call-cells	39940
@NP	the first few weeks	39963
@NP	the injured spinal cord	39991
@NP	a suitable environment	40035
@NP	Johansson	40059
@NP	et al. , 1999 ; Ceccatelli et al. , 2004	40069
@NP	et al.	40069
@NP	1999 ; Ceccatelli et al.	40077
@NP	1999	40077
@NP	Ceccatelli et al.	40083
@NP	Ceccatelli	40083
@NP	et al.	40094
@NP	2004	40102
@NP	contrast	40112
@NP	animals undergoing transplant of the scaffold containing both cells types	40122
@NP	animals	40122
@NP	transplant of the scaffold containing both cells types	40141
@NP	transplant	40141
@NP	the scaffold containing both cells types	40155
@NP	the scaffold	40155
@NP	cells types	40184
@NP	significantly improved motor function	40203
@NP	the remaining animals	40253
@NP	rats in SCI with cell	40282
@NP	rats	40282
@NP	SCI with cell	40290
@NP	SCI	40290
@NP	cell	40299
@NP	scaffold group	40311
@NP	90 days post-injury	40351
@NP	recovery	40389
@NP	their modified BBB scores	40415
@NP	the scaffold-alone	40451
@NP	a significant role	40485
@NP	glial scar formation	40516
@NP	the presence of both cells types in the scaffold	40538
@NP	the presence	40538
@NP	cells types	40559
@NP	the scaffold	40574
@NP	the greatest recovery	40596
@NP	The mechanisms whereby the scaffold plus cells	40619
@NP	The mechanisms	40619
@NP	the scaffold plus cells	40642
@NP	the scaffold	40642
@NP	cells	40660
@NP	the functional recovery process	40686
@NP	further explored	40729
@NP	further	40729
@NP	conclusion	40750
@NP	our findings	40762
@NP	OECs and ADSCs	40802
@NP	this new human serum-derived spongy scaffold	40818
@NP	motor function recovery in SCI rats	40882
@NP	motor function recovery	40882
@NP	SCI rats	40909
@NP	future direction	40930
@NP	studies designed to test the safety and potential of this scaffold	40951
@NP	studies	40951
@NP	the safety and potential of this scaffold	40976
@NP	the safety and potential	40976
@NP	this scaffold	41004
@NP	Acknowledgements .	41020
@VP	seeded with adipose-derived stem cells and olfactory ensheathing cells	36
@VP	injured rats Amaia Ferrero-Gutierrez1 * , Yolanda Menendez-Menendez1 *	133
@VP	have contributed equally to this work	511
@VP	contributed equally to this work	516
@VP	predict promising new treatments for patients with SCI or other nerve injuries	659
@VP	are instructed to form a tissue in a controlled manner	797
@VP	instructed to form a tissue in a controlled manner	801
@VP	to form a tissue in a controlled manner	812
@VP	form a tissue in a controlled manner	815
@VP	are considered promising candidates for the treatment of SCI	1103
@VP	considered promising candidates for the treatment of SCI	1107
@VP	have the ability to differentiate into neural lineages	1175
@VP	to differentiate into neural lineages	1192
@VP	differentiate into neural lineages	1195
@VP	adhered to the scaffold	1281
@VP	remained viable	1306
@VP	expressed specific markers of their cell types when cultured in the scaffold	1326
@VP	cultured in the scaffold	1378
@VP	treated with scaffold plus cells	1409
@VP	were improved over those recorded in control injured	1519
@VP	improved over those recorded in control injured	1524
@VP	recorded in control injured	1544
@VP	injured	1564
@VP	identified using histological and immunohistochemical techniques	1634
@VP	using histological and immunohistochemical techniques	1645
@VP	reducing glial scar formation and filling of the lesion cavity with cells	1782
@VP	expressing markers of neurons and axons at the injury site	1935
@VP	produces partial or complete sensory and motor loss below the level of injury	2244
@VP	can be seen in both gray and white matter -LRB- Balentine , 1978 -RRB-	2403
@VP	be seen in both gray and white matter -LRB- Balentine , 1978 -RRB-	2407
@VP	seen in both gray and white matter -LRB- Balentine , 1978 -RRB-	2410
@VP	causes the death of neurons and glial cells as well as axon tract injury	2471
@VP	are not replaced and injured axons are not spontaneously regenerated	2564
@VP	replaced and injured axons are not spontaneously regenerated	2572
@VP	replaced	2572
@VP	injured axons are not spontaneously regenerated	2585
@VP	are not spontaneously regenerated	2599
@VP	are permanent -LRB- Cadelli et al. , 1992 ; Schwab and Caroni , 2008 -RRB-	2655
@VP	produced by SCI	2734
@VP	poses many obstacles for promoting tissue and cell regeneration	2750
@VP	promoting tissue and cell regeneration	2775
@VP	surrounded by a glial and fibrous scar , composed of mainly reactive astrocytes	2915
@VP	composed of mainly reactive astrocytes	2955
@VP	occurs after SCI	3147
@VP	designed to either maintain or recover neuronal functions	3349
@VP	to either maintain or recover neuronal functions	3358
@VP	maintain or recover neuronal functions	3368
@VP	regenerating injured axons	3423
@VP	are capable of migrating into and through astrocytic scars	3679
@VP	migrating into and through astrocytic scars	3694
@VP	is however limited by the availability of functional cells	4190
@VP	limited by the availability of functional cells	4201
@VP	is based on the use of adult mesenchymal stem cells -LRB- MSC -RRB-	4280
@VP	based on the use of adult mesenchymal stem cells -LRB- MSC -RRB-	4283
@VP	to differentiate towards a neuronal phenotype in vitro as well as in vivo	4383
@VP	differentiate towards a neuronal phenotype in vitro as well as in vivo	4386
@VP	to treat neurological disorders	4494
@VP	treat neurological disorders	4497
@VP	has attracted the attention of researchers -LRB- Kang et al. , 2003 -RRB-	4526
@VP	attracted the attention of researchers -LRB- Kang et al. , 2003 -RRB-	4530
@VP	used to induce MSC differentiation into neurons and glial cells in vitro	4805
@VP	to induce MSC differentiation into neurons and glial cells in vitro	4810
@VP	induce MSC differentiation into neurons and glial cells in vitro	4813
@VP	transplanted with MSCs	5043
@VP	may be caused by the release of trophic factors via a paracrine effect	5066
@VP	be caused by the release of trophic factors via a paracrine effect	5070
@VP	caused by the release of trophic factors via a paracrine effect	5073
@VP	used in the present study	5316
@VP	serves as a three-dimensional substrate	5400
@VP	is prepared from the patient 's own blood	5494
@VP	prepared from the patient 's own blood	5497
@VP	could have many tissue-engineering applications	5688
@VP	have many tissue-engineering applications	5694
@VP	to repair bone defects -LRB- Gallego et al. , 2009 , 2010 -RRB-	5806
@VP	repair bone defects -LRB- Gallego et al. , 2009 , 2010 -RRB-	5809
@VP	seeded in a novel serum-derived albumin scaffold on SCI	6005
@VP	described	6148
@VP	to patent WO2008/119855	6211
@VP	patent WO2008/119855	6214
@VP	was obtained from a blood bank and kept for 30 min at 37 °C	6274
@VP	was obtained from a blood bank	6274
@VP	obtained from a blood bank	6278
@VP	kept for 30 min at 37 °C	6309
@VP	was centrifuged for 15 min at 2000 g	6350
@VP	centrifuged for 15 min at 2000 g	6354
@VP	transferred to a 5 ml disposable syringe	6497
@VP	was frozen and kept at -70 °C overnight	6644
@VP	frozen and kept at -70 °C overnight	6648
@VP	was cut open and the frozen solution	6701
@VP	cut open and the frozen solution	6705
@VP	lyophilized for 48 h	6742
@VP	immersing for 1 h in each dilution	6821
@VP	obtained	6882
@VP	was removed	7164
@VP	removed	7168
@VP	induced by isoflurane inhalation -LRB- Esteve laboratories , Milan , Italy -RRB-	7422
@VP	chopped	7586
@VP	placed in a test tube	7598
@VP	was shaken and digested for 1 h at 37 °C	7727
@VP	shaken and digested for 1 h at 37 °C	7731
@VP	was stopped by adding fetal bovine serum -LRB- FBS ; Gibco Invitrogen -RRB-	7778
@VP	stopped by adding fetal bovine serum -LRB- FBS ; Gibco Invitrogen -RRB-	7782
@VP	adding fetal bovine serum -LRB- FBS ; Gibco Invitrogen -RRB-	7793
@VP	were cultured in a controlled atmosphere -LRB- 37 °C , 5 % CO2 -RRB- at 48 h	8237
@VP	cultured in a controlled atmosphere -LRB- 37 °C , 5 % CO2 -RRB- at 48 h	8242
@VP	was first replaced	8313
@VP	first replaced	8317
@VP	removed	8353
@VP	was replenished every 2-3 days	8385
@VP	replenished every 2-3 days	8389
@VP	digested with trypsin -LRB- 0.25 % w/v ; Gibco Invitrogen -RRB-	8469
@VP	passaged four times before their use	8526
@VP	used to purify OECs from these primary OB cultures	8839
@VP	to purify OECs from these primary OB cultures	8844
@VP	purify OECs from these primary OB cultures	8847
@VP	plating	8990
@VP	detached with 0.25 % trypsin	9234
@VP	centrifuged -LRB- 200 g ; 10 min -RRB-	9263
@VP	incubated with the p-75 NGFR antibody for 45 min at room temperature	9296
@VP	washed twice in PBS/BSA/EDTA	9387
@VP	coated with goat anti-mouse IgG	9504
@VP	attached to the magnetic beads	9615
@VP	to retain the magnetic bead-OEC complexes	9753
@VP	retain the magnetic bead-OEC complexes	9756
@VP	were washed three times in PBS/BSA/EDTA	9812
@VP	washed three times in PBS/BSA/EDTA	9817
@VP	followed by incubation for 48 h in an OEC culture medium	9974
@VP	supplemented with 10 % FBS , 100 U/ml penicillin , and 100 μg/ml streptomycin	10100
@VP	were trypsinized and counted in a Neubauer hemocytometer	10275
@VP	trypsinized and counted in a Neubauer hemocytometer	10280
@VP	released	10343
@VP	were suspended in DMEM containing 10 % FBS	10352
@VP	suspended in DMEM containing 10 % FBS	10357
@VP	containing 10 % FBS	10375
@VP	had been removed	10409
@VP	been removed	10413
@VP	removed	10418
@VP	containing 10 % FBS , 100 U/ml penicillin	10491
@VP	1x106 ADSCs -LRB- 0.5 ml -RRB- and 5x105 OECs -LRB- 0.5 ml -RRB-	10628
@VP	were seeded onto the scaffolds in the wells	10673
@VP	seeded onto the scaffolds in the wells	10678
@VP	were kept under shaking for 48 h to allow the cells to attach	10732
@VP	kept under shaking for 48 h to allow the cells to attach	10737
@VP	shaking for 48 h to allow the cells to attach	10748
@VP	to allow the cells to attach	10765
@VP	allow the cells to attach	10768
@VP	to attach	10784
@VP	attach	10787
@VP	was replenished twice per week	10814
@VP	replenished twice per week	10818
@VP	were maintained for 7 days at 37 °C in a humidified atmosphere of 5 % CO2	10856
@VP	maintained for 7 days at 37 °C in a humidified atmosphere of 5 % CO2	10861
@VP	The following in vitro study groups	10950
@VP	were established : Scaffold control -LRB- n = 5 -RRB- : Scaffold alone	10986
@VP	established : Scaffold control -LRB- n = 5 -RRB- : Scaffold alone	10991
@VP	co-cultured in the scaffold	11094
@VP	Scanning electron microscopy -LRB- SEM -RRB-	11123
@VP	were observed by scanning electron microscopy	11241
@VP	observed by scanning electron microscopy	11246
@VP	using CO2 -LRB- Baltec CDP 030 critical point dryer -RRB-	11549
@VP	then viewed by SEM -LRB- JEOL JSM 6100 , Tokyo , Japan -RRB-	11646
@VP	fixed overnight in 4 % paraformaldehyde -LRB- Panreac -RRB- in 0.1 M PBS at 4 °C	11748
@VP	washing twice in PBS	11824
@VP	were placed in PBS	12081
@VP	placed in PBS	12086
@VP	covered with coverslips	12267
@VP	analyzed using the equipment 's image analysis software	12468
@VP	using the equipment 's image analysis software	12477
@VP	fixed overnight in 4 % paraformaldehyde in 0.1 M PBS at 4 °C	12572
@VP	frozen in isopentane	12632
@VP	embedded in OCT medium	12657
@VP	5 - to 10 μm-thick cut on a cryostat	12694
@VP	were mounted on glass slides , placed in PBS	12770
@VP	mounted on glass slides , placed in PBS	12775
@VP	placed in PBS	12800
@VP	blocked after 30 min with 1 % H2O2	12840
@VP	incubating sections for at least 30 min in 5 % BSA -LRB- Merck -RRB- in PBS	12919
@VP	be localized using the REAL EnVision Detection system kit -LRB- Dako -RRB-	13493
@VP	using the REAL EnVision Detection system kit -LRB- Dako -RRB-	13506
@VP	' -3	13576
@VP	staining vimentin and p75-NGFR-positive cells brown	13621
@VP	Labeled	13674
@VP	were mounted in a hydrophobic medium -LRB- Entellan ; Merck -RRB-	13691
@VP	mounted in a hydrophobic medium -LRB- Entellan ; Merck -RRB-	13696
@VP	stained with hematoxylin and eosin -LRB- H&E -RRB- for microscopy examination	13767
@VP	analyzed using the equipment 's image analysis software	13969
@VP	using the equipment 's image analysis software	13978
@VP	used	14084
@VP	leaving a small hinge uncut -LRB- the cord is thus around 80 % transected -RRB-	14176
@VP	is thus around 80 % transected	14214
@VP	around 80 % transected	14222
@VP	results in the formation of a central cavity although some axons are spared	14251
@VP	are spared	14316
@VP	spared	14320
@VP	injured in this manner	14336
@VP	have symmetrical paraplegia	14359
@VP	are incapable of hindlimb movement immediately after surgery	14391
@VP	matched for age -LRB- 12 weeks old -RRB- and weight -LRB- mean 250 g -RRB-	14560
@VP	were anesthetized by isoflurane inhalation -LRB- Esteve -RRB-	14625
@VP	exposed by laminectomy at vertebral level T7	14724
@VP	using fine iridectomy scissors -LRB- FST , Heidelberg , Germany -RRB-	14820
@VP	were randomly and blindly assigned to the different treatment groups	14899
@VP	assigned to the different treatment groups	14925
@VP	is injured	14990
@VP	injured	14993
@VP	produced leaves enough room for scaffold insertion	15025
@VP	leaves enough room for scaffold insertion	15034
@VP	emptied manually once a day until they had recovered autonomic bladder function	15375
@VP	had recovered autonomic bladder function	15414
@VP	recovered autonomic bladder function	15418
@VP	kept in a climate-controlled , pathogen-free animal house	15470
@VP	subjected to a12 h light-dark cycle	15531
@VP	were available ad libitum	15583
@VP	were established : Group 1 -LRB- G1 -RRB- , SCI-only : rats subjected to SCI	15933
@VP	established : Group 1 -LRB- G1 -RRB- , SCI-only : rats subjected to SCI	15938
@VP	subjected to SCI	15980
@VP	left untreated	15997
@VP	subjected to SCI and then treated with a cell-free scaffold	16048
@VP	subjected to SCI	16048
@VP	then treated with a cell-free scaffold	16069
@VP	subjected to SCI and then treated with a scaffold seeded with ADSCs and OECs	16159
@VP	subjected to SCI	16159
@VP	then treated with a scaffold seeded with ADSCs and OECs	16180
@VP	seeded with ADSCs and OECs	16209
@VP	Modified BBB test Overall motor performance of the animals	16237
@VP	test Overall motor performance of the animals	16250
@VP	were place on a methacrylate walkway 1 m long	16399
@VP	to enable the observation of hind-limb movements	16525
@VP	enable the observation of hind-limb movements	16528
@VP	had to walk the runway three times	16587
@VP	to walk the runway three times	16591
@VP	walk the runway three times	16594
@VP	was performed in a double-blinded manner	16736
@VP	performed in a double-blinded manner	16740
@VP	was not the same as described in the original score	16953
@VP	the same as described in the original score	16961
@VP	are able to raise their tails early in the recovery process	17017
@VP	to raise their tails early in the recovery process	17026
@VP	raise their tails early in the recovery process	17029
@VP	were given for a raised tail position -LRB- Demjen et al. , 2004 -RRB-	17103
@VP	given for a raised tail position -LRB- Demjen et al. , 2004 -RRB-	17108
@VP	were recorded using a video camera while being tested	17276
@VP	recorded using a video camera while being tested	17281
@VP	using a video camera while being tested	17290
@VP	being tested	17317
@VP	tested	17323
@VP	was then scored on digitalized videos played at one-quarter speed	17353
@VP	scored on digitalized videos played at one-quarter speed	17362
@VP	played at one-quarter speed	17391
@VP	was 3 due to audiovisual problems	17490
@VP	were sacrificed 90 days after surgery	17617
@VP	sacrificed 90 days after surgery	17622
@VP	perfused with saline solution , followed by ice-cold 4 % paraformaldehyde	17697
@VP	were dissected and post-fixed for an additional 48-72 h in the same fixative	17794
@VP	dissected and post-fixed for an additional 48-72 h in the same fixative	17799
@VP	dissected	17799
@VP	post-fixed for an additional 48-72 h in the same fixative	17813
@VP	replenished each day	17976
@VP	centered at the injury site analyzed	18061
@VP	analyzed	18089
@VP	were dehydrated in a graded series of ethanol dilutions and embedded in paraffin	18139
@VP	dehydrated in a graded series of ethanol dilutions and embedded in paraffin	18144
@VP	graded series of ethanol dilutions	18160
@VP	obtained using a microtome -LRB- model H310 ; Micron , Waldorf , Germany -RRB-	18247
@VP	using a microtome -LRB- model H310 ; Micron , Waldorf , Germany -RRB-	18256
@VP	deparaffinated in xylene	18314
@VP	rehydrated in an ethanol series	18340
@VP	placed in PBS	18377
@VP	rinsing in PBS to quench endogenous peroxidase activity	18594
@VP	to quench endogenous peroxidase activity	18609
@VP	quench endogenous peroxidase activity	18612
@VP	was blocked by incubating sections for al least 30 min in 5 % BSA in PBS	18723
@VP	blocked by incubating sections for al least 30 min in 5 % BSA in PBS	18727
@VP	incubating sections for al least 30 min in 5 % BSA in PBS	18738
@VP	using the anti-tyrosine hydroxylase primary antibody	18801
@VP	placed in boiling citrate buffer -LRB- pH 6 -RRB- in a pressure cooker	18873
@VP	boiling citrate buffer -LRB- pH 6 -RRB- in a pressure cooker	18883
@VP	incubated with these primary antibodies overnight at 4 °C in a humid chamber	19542
@VP	be localized using the REAL EnVision Detection system kit -LRB- Dako -RRB-	19832
@VP	using the REAL EnVision Detection system kit -LRB- Dako -RRB-	19845
@VP	uses a DAB-like chromogen	19907
@VP	were counterstained with hematoxylin	19947
@VP	counterstained with hematoxylin	19952
@VP	Labeled	19985
@VP	were mounted in a hydrophobic medium -LRB- Entellan ; Merck -RRB-	20002
@VP	mounted in a hydrophobic medium -LRB- Entellan ; Merck -RRB-	20007
@VP	analyzed using the equipment 's image analysis software	20190
@VP	using the equipment 's image analysis software	20199
@VP	used the program Graphpad InStat for Windows	20295
@VP	using a Student 's ttest	20448
@VP	are provided as means ± S.E.M.	20478
@VP	provided as means ± S.E.M.	20482
@VP	± S.E.M.	20500
@VP	indicate significant differences relevant to the discussion of the data	20522
@VP	was set at p < 0.05	20621
@VP	set at p < 0.05	20625
@VP	results recorded in the three treatment groups	20702
@VP	recorded in the three treatment groups	20710
@VP	adhered to the scaffold	20947
@VP	incubating the cells in the scaffold for 7 days	21114
@VP	were visualized by staining with the DNA-binding fluorescent dye DAPI	21175
@VP	visualized by staining with the DNA-binding fluorescent dye DAPI	21180
@VP	staining with the DNA-binding fluorescent dye DAPI	21194
@VP	dye DAPI	21236
@VP	Note the autofluorescence of the scaffold in -LRB- A -RRB-	21246
@VP	loaded with ADSCs and OECs	21337
@VP	stained with vimentin -LRB- D -RRB-	21559
@VP	stained with p75	21594
@VP	was significantly improved over the rate observed in G1 -LRB- * p < 0.05 -RRB-	21908
@VP	improved over the rate observed in G1 -LRB- * p < 0.05 -RRB-	21926
@VP	observed in G1 -LRB- * p < 0.05 -RRB-	21949
@VP	represent the means ± S.E.M.	21982
@VP	± S.E.M.	22002
@VP	seeded scaffold	22063
@VP	seeded scaffold group -LRB- G3 , C -RRB-	22241
@VP	were filled with cells	22445
@VP	filled with cells	22450
@VP	was partially degraded and filled with cells	22503
@VP	degraded and filled with cells	22517
@VP	were filled with ADSCs and OECs	22622
@VP	filled with ADSCs and OECs	22627
@VP	was partially degraded and filled with cells	22689
@VP	degraded and filled with cells	22703
@VP	seeded scaffold group -LRB- G3 -RRB-	22922
@VP	Note the partially degraded scaffold in these images	22950
@VP	showing positivity for GFAP	23022
@VP	can be seen G1 compared to G3	23050
@VP	be seen G1 compared to G3	23054
@VP	seen G1 compared to G3	23057
@VP	showing positivity for GAP-43	23113
@VP	can be seen at the injury site within the neoformed tissue in G3 compared to G1	23143
@VP	be seen at the injury site within the neoformed tissue in G3 compared to G1	23147
@VP	seen at the injury site within the neoformed tissue in G3 compared to G1	23150
@VP	showing positivity for ß-III tubulin	23256
@VP	can be seen at the injury site within the neoformed tissue in G3	23293
@VP	be seen at the injury site within the neoformed tissue in G3	23297
@VP	seen at the injury site within the neoformed tissue in G3	23300
@VP	showing positivity for ß-galactosidase	23538
@VP	can be seen within the neoformed tissue in G3 compared to G1	23577
@VP	be seen within the neoformed tissue in G3 compared to G1	23581
@VP	seen within the neoformed tissue in G3 compared to G1	23584
@VP	were observed by SEM	23774
@VP	observed by SEM	23779
@VP	recognized according to their morphology	23812
@VP	could be seen adhered to the scaffold	23854
@VP	be seen adhered to the scaffold	23860
@VP	seen adhered to the scaffold	23863
@VP	adhered to the scaffold	23868
@VP	may be seen in Fig. 1A	23941
@VP	be seen in Fig. 1A	23945
@VP	seen in Fig. 1A	23948
@VP	ranged from 50 to 150 μm -LRB- Fig. 1 -RRB-	23979
@VP	sized and shaped sheet-like structure	24033
@VP	was observed	24071
@VP	observed	24075
@VP	pores were interconnected	24100
@VP	were interconnected	24106
@VP	interconnected	24111
@VP	provides suitable spaces for cells to grow into the scaffold	24132
@VP	to grow into the scaffold	24167
@VP	grow into the scaffold	24170
@VP	incubated in the scaffold for 7 days	24223
@VP	revealed that OECs and ADSCs adhered to the scaffold -LRB- Fig. 1B -RRB-	24260
@VP	adhered to the scaffold -LRB- Fig. 1B -RRB-	24289
@VP	cultured in the scaffold The effect of the scaffold on cell viability	24376
@VP	was determined by DNA staining using DAPI	24446
@VP	determined by DNA staining using DAPI	24450
@VP	using DAPI	24477
@VP	incubating the ADSCs and OECs for 7 days in the scaffold	24495
@VP	had regular contours	24584
@VP	is a characteristic of live cells -LRB- Fig. 2A , B -RRB-	24645
@VP	were characterized by immunohistochemical staining for vimentin and p75	24708
@VP	characterized by immunohistochemical staining for vimentin and p75	24713
@VP	were vimentin positive -LRB- Fig. 2D -RRB-	24798
@VP	were positive for p75 -LRB- Fig. 2E -RRB-	24841
@VP	used	24907
@VP	causes symmetric paraplegia in the hind-limbs	24977
@VP	using the modified BBB locomotor score -LRB- Basso et al. , 1995 -RRB-	25081
@VP	were 0	25355
@VP	was the difference significant	25595
@VP	indicates no motor defects	26002
@VP	stabilize in the group , and mean score after 90 days of follow-up was 9.1 ± 0.1	26064
@VP	stabilize in the group	26064
@VP	mean score after 90 days of follow-up was 9.1 ± 0.1	26092
@VP	was 9.1 ± 0.1	26130
@VP	recorded at 45 days	26195
@VP	may be seen in figure 3	26262
@VP	be seen in figure 3	26266
@VP	seen in figure 3	26269
@VP	were observed at any of the treatment times	26337
@VP	observed at any of the treatment times	26342
@VP	indicated by the slopes of plots of scores against time	26528
@VP	performed on all groups of animals after their sacrifice 90 days post-injury	26727
@VP	were slightly filled with bundles of tissue	26941
@VP	filled with bundles of tissue	26955
@VP	was no evidence of significant tissue regeneration -LRB- Fig. 4A -RRB-	26996
@VP	was completely filled with cells 90 days post-injury	27177
@VP	filled with cells 90 days post-injury	27192
@VP	suggesting reabsorption of the scaffold and replacement with new tissue	27322
@VP	was used to evaluate the extent of scar tissue formation	27406
@VP	used to evaluate the extent of scar tissue formation	27410
@VP	to evaluate the extent of scar tissue formation	27415
@VP	evaluate the extent of scar tissue formation	27418
@VP	see Table 1	27556
@VP	observed in SCI with cell	27611
@VP	seeded scaffold group was not induced by collagen scar inhibition	27637
@VP	was not induced by collagen scar inhibition	27659
@VP	induced by collagen scar inhibition	27667
@VP	did not inhibit collagen synthesis after SCI	27803
@VP	inhibit collagen synthesis after SCI	27811
@VP	using an antibody against the astrocyte marker GFAP	27948
@VP	confirms the presence of glial scar in this control group -LRB- Fig. 5A -RRB-	28336
@VP	not shown	28512
@VP	was able to inhibit glial scar formation	28575
@VP	to inhibit glial scar formation	28584
@VP	inhibit glial scar formation	28587
@VP	suppressed this glial scar	28654
@VP	used different specific antibodies	28782
@VP	act as a bridge that permitted the passage of ascending and descending axons	28876
@VP	permitted the passage of ascending and descending axons	28897
@VP	ascending and descending axons	28922
@VP	see Table 1	29100
@VP	not shown	29286
@VP	were GAP-43 positive rostral to the scaffold -LRB- injury site -RRB-	29373
@VP	took place	29501
@VP	was filled with the cell-loaded scaffolds	29519
@VP	filled with the cell-loaded scaffolds	29523
@VP	suggests that the newly formed tissue contained neurons or neuronal elements	29562
@VP	contained neurons or neuronal elements	29600
@VP	not shown	29956
@VP	not shown	30058
@VP	to examine the presence of neural and astroglial cells at the site of injury	30079
@VP	examine the presence of neural and astroglial cells at the site of injury	30082
@VP	observed during developmental growth	30241
@VP	expressing ß-galactosidase	30312
@VP	see Table 1	30340
@VP	seeded	30581
@VP	showed positive immunostaining for the GAP-43 antibody at the injury site	30696
@VP	were GAP-43 negative -LRB- Fig. 5B , F -RRB-	30851
@VP	were both negative for this antibody -LRB- Fig. 5D , H -RRB-	31018
@VP	developed by our research group	31412
@VP	using cultured osteoblasts in a rat model -LRB- Gallego et al. , 2010 -RRB-	31534
@VP	cultured osteoblasts in a rat model -LRB- Gallego et al. , 2010 -RRB-	31540
@VP	engineered implants	31615
@VP	impairs cell culture	31728
@VP	crosslinking incorporated in our technique	31780
@VP	incorporated in our technique	31793
@VP	eliminates the toxic properties of this agent -LRB- Gallego et al. , 2010 -RRB-	31830
@VP	developed	31953
@VP	is an appropriate substrate for nerve tissue regeneration	31963
@VP	can potentially be used as an autologous scaffold	32025
@VP	be used as an autologous scaffold	32041
@VP	used as an autologous scaffold	32044
@VP	has the advantage that it is easy and nonexpensive to produce	32094
@VP	is easy and nonexpensive to produce	32120
@VP	to produce	32145
@VP	produce	32148
@VP	is very important when considering scaffolds for tissue engineering	32172
@VP	considering scaffolds for tissue engineering	32195
@VP	pores create good mass transfer properties and increase cell viability	32273
@VP	create good mass transfer properties and increase cell viability	32279
@VP	is usually required to allow tissue ingrowth -LRB- Zeltinger et al. , 2001 -RRB-	32401
@VP	required to allow tissue ingrowth -LRB- Zeltinger et al. , 2001 -RRB-	32412
@VP	to allow tissue ingrowth -LRB- Zeltinger et al. , 2001 -RRB-	32421
@VP	allow tissue ingrowth -LRB- Zeltinger et al. , 2001 -RRB-	32424
@VP	observed in longitudinal sections than cross sections of scaffold	32575
@VP	are thus elongated in shape and highly interconnected	32654
@VP	thus elongated in shape	32658
@VP	confirming a suitable architecture for cell penetration	32709
@VP	used in our study	32820
@VP	creates sufficient space for ADSC neurotransdifferentiation	32937
@VP	approaches to SCI	33051
@VP	is a highly invasive procedure	33286
@VP	have turned to the use of adipose tissue as an alternative rich source of MSC	33330
@VP	turned to the use of adipose tissue as an alternative rich source of MSC	33335
@VP	make them ideal candidates for cell transplant therapy after SCI	33456
@VP	avoiding immune rejection -LRB- Wang et al. , 2007 -RRB-	33578
@VP	easily obtained from subcutaneous adipose tissue	33670
@VP	expanded	33720
@VP	stored -LRB- Zuk et al. , 2001 ; Yarak and Okamoto , 2010 -RRB-	33733
@VP	co-transplanted both cell types in our rat model of SCI	34169
@VP	maintained their viability and phenotype when used to seed the scaffold	34279
@VP	used to seed the scaffold	34325
@VP	co-culturing for 7 days in the scaffolds	34358
@VP	were implanted in the injured rats	34406
@VP	implanted in the injured rats	34411
@VP	takes place 20-30 days	34518
@VP	implant	34547
@VP	implant site will need to be investigated in future studies	34633
@VP	will need to be investigated in future studies	34646
@VP	need to be investigated in future studies	34651
@VP	to be investigated in future studies	34656
@VP	be investigated in future studies	34659
@VP	investigated in future studies	34662
@VP	recorded in our three experimental groups at 90 days post-injury	34790
@VP	observed in SCI with cell	34881
@VP	recorded in controls at this time point	34944
@VP	was significant	34984
@VP	starts a few weeks after transplantation -LRB- Vaquero et al. , 2006 -RRB-	35213
@VP	stabilized at around 9 -LRB- from 45 days post-injury -RRB-	35450
@VP	supported dorsal stepping and no plantar stepping	35631
@VP	stepping	35648
@VP	stepping	35672
@VP	were left untreated	35736
@VP	left untreated	35741
@VP	modified BBB scores of approximately 5 , and SCI + scaffold group	35783
@VP	achieved a slightly lower score -LRB- approximately 4 -RRB-	35848
@VP	was found to promote functional recovery after SCI	36080
@VP	found to promote functional recovery after SCI	36084
@VP	to promote functional recovery after SCI	36090
@VP	promote functional recovery after SCI	36093
@VP	contribute to supporting the neuronal differentiation of implanted BMSCs	36318
@VP	supporting the neuronal differentiation of implanted BMSCs	36332
@VP	To elucidate possible mechanisms underlying the observed functional recovery	36392
@VP	elucidate possible mechanisms underlying the observed functional recovery	36395
@VP	underlying the observed functional recovery	36425
@VP	used several histology and immunohistochemistry techniques	36473
@VP	seeded scaffold -LRB- G3 -RRB- or a SCI + scaffold -LRB- G2 -RRB-	36774
@VP	was completely filled with cells	36841
@VP	filled with cells	36856
@VP	implanted within the scaffold	36904
@VP	filling the spinal cord cavity	36949
@VP	could act as a bridge for the passage of descending axons	37013
@VP	act as a bridge for the passage of descending axons	37019
@VP	infilled spinal cord cavity observed after the implant of the scaffold alone	37112
@VP	observed after the implant of the scaffold alone	37140
@VP	implant of the scaffold alone	37159
@VP	achieve this by migrating to the lesion site in response to injury	37232
@VP	migrating to the lesion site in response to injury	37248
@VP	born -LRB- call-cells -RRB- in the spinal cord	37348
@VP	is assumed they replace injured cells -LRB- McDonald and Becker , 2003 -RRB-	37427
@VP	assumed they replace injured cells -LRB- McDonald and Becker , 2003 -RRB-	37430
@VP	replace injured cells -LRB- McDonald and Becker , 2003 -RRB-	37443
@VP	could act as a good support for these call-cells	37517
@VP	act as a good support for these call-cells	37523
@VP	was histologically	37770
@VP	immunohistochemically addressed 90 days after scaffold implant	37793
@VP	implant	37848
@VP	identified by Sirius red staining	37892
@VP	be seen at the margins of the spinal cord cavity in all the treatment groups	37932
@VP	seen at the margins of the spinal cord cavity in all the treatment groups	37935
@VP	has usually reached a steady state	38266
@VP	reached a steady state	38278
@VP	transplanted into lesioned spinal cords -LRB- Verdu et al. , 2001 -RRB-	38541
@VP	observed in the spinal cords of the scaffold-treated animals	38636
@VP	reducing their reactivity and creating a protective environment	38791
@VP	reducing their reactivity	38791
@VP	creating a protective environment	38821
@VP	suggesting that the newly formed tissue contains neurons and glial cells	39005
@VP	contains neurons and glial cells	39045
@VP	permitted the passage of descending and ascending neurons	39169
@VP	descending and ascending neurons	39194
@VP	revealed by the specific antibodies used	39231
@VP	used	39267
@VP	observed in control rats	39371
@VP	could be attributed to the neoformation of the axons detected	39396
@VP	be attributed to the neoformation of the axons detected	39402
@VP	attributed to the neoformation of the axons detected	39405
@VP	detected	39449
@VP	is incapable of improving functional recovery	39487
@VP	improving functional recovery	39503
@VP	contributing to glial scar inhibition	39610
@VP	could also act as a support for callcells	39652
@VP	act as a support for callcells	39663
@VP	fill the cord cavity	39855
@VP	undergoing transplant of the scaffold containing both cells types	40130
@VP	containing both cells types	40168
@VP	showed significantly improved motor function compared to the remaining animals	40196
@VP	continued to show recovery , as indicated by their modified BBB scores	40371
@VP	to show recovery	40381
@VP	show recovery	40384
@VP	indicated by their modified BBB scores	40402
@VP	seemed to play a significant role in reducing glial scar formation	40470
@VP	to play a significant role in reducing glial scar formation	40477
@VP	play a significant role in reducing glial scar formation	40480
@VP	reducing glial scar formation	40507
@VP	achieved the greatest recovery	40587
@VP	are able to improve the functional recovery process need to be further explored	40666
@VP	to improve the functional recovery process need to be further explored	40675
@VP	improve the functional recovery process need to be further explored	40678
@VP	need to be further explored	40718
@VP	to be further explored	40723
@VP	be further explored	40726
@VP	explored	40737
@VP	loaded with OECs and ADSCs	40790
@VP	is able to improve motor function recovery in SCI rats	40863
@VP	to improve motor function recovery in SCI rats	40871
@VP	improve motor function recovery in SCI rats	40874
@VP	designed to test the safety and potential of this scaffold	40959
@VP	to test the safety and potential of this scaffold	40968
@VP	test the safety and potential of this scaffold	40971
